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ABSTRACT 
Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative 
disease that may occur in two clinically indistinguishable forms: sporadic (sALS) 
and familial (fALS), the latter linked to several gene mutations, mostly inheritable 
in a dominant fashion [Rosen et al., 1993]. The disease is characterized by selective 
and progressive degeneration of upper and lower motor neurons, leading to 
muscle weakness, atrophy and evolving to complete paralysis that results in 
patient death in 2 to 5 years after symptoms onset. 
Research on ALS has mainly relied so far on experimental rodent 
models carrying a variety of Cu/Zn Superoxide Dismutase 1 (SOD1) mutations. 
Currently, the most widely employed model is a transgenic mouse with a glycine 
to alanine conversion at the 93rd codon (G93A) of the SOD1 gene. These mice 
reliably reproduce the ALS patients phenotype progression, developing a rapidly 
progressive motor neuron degeneration. Death occurs about four months after 
symptoms onset [Turner & Talbot, 2008], not reflecting the disease course in human 
patients. Although the use of these murine models is currently widespread both in 
clinical trials and in basic research, aimed at a resolution of the pathogenic 
mechanisms underlying the disease, doubts have been recently raised, from 
numerous reliable sources [Schnabel, 2008; Benatar, 2007; Van Den Bosch, 2011; 
Gordon et al., 2007] about rodents suitability to faithfully reproduce the human 
disease. Since human and rodent species differ in life-span, physiology, anatomy 
and biochemical aspects, data extrapolation has proved to be difficult. As a matter 
of fact, encouraging results of drug tests in rodents have never been so far 
successfully translated to humans, and, in some cases, molecules delaying disease 
progression in transgenic mice, such as minocycline, have resulted even 
detrimental in ALS patients [Scott et al., 2008] also because of the heterogeneity of 
mouse genetic background [Schnabel, 2008].  
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The scientific community has already accepted swine as an attractive 
model, alternative to non-human primates, for pharmacological and surgical 
testing as well as for biomedical research on the basis of its anatomical, 
physiological and biochemical features that are more closely related to human 
species than the rodent ones. Furthermore, the prospect of obtaining genetically 
modified pigs further extended their biomedical potential especially to mimic 
inherited human diseases [Bendixen et al., 2010].  
In particular, regarding Central Nervous System (CNS) anatomy, pig brain cortical 
surface resembles human gyrencephalic neocortex and similarities with the 
human brain have also been demonstrated for the hippocampus, subcortical and 
diencephalic nuclei and brainstem structures. Furthermore, pig brain size permits 
an easy identification of cortical and subcortical structures by conventional 
imaging techniques and offers invaluable opportunities for microsurgical 
techniques and intrathecal drugs administration.  
Consistently, the swine large size and long lifespan allow to perform numerous 
and repetitive samplings from the same animal, thus enabling to get a higher 
amount of data to characterize in detail preclinical and clinical phases. The longer 
lifespan makes swine also a suitable animal model for long-term evaluation of 
safety and efficacy of innovative therapies. Moreover cloning techniques are well 
established in this species, allowing thus to solve problems related to the 
variability of genetic background.  
On this basis, our group has produced by in vitro transfection of 
cultured somatic cells combined with Somatic Cell Nuclear Transfer (SCNT) the 
first swine ALS model.  
To achieve this goal, an ubiquitous SOD1G93A expression vector has been used, 
which is characterized by the ability to maintain high expression levels through 
the next generation of pigs [Brunetti et al., 2008], wherein the pCAGGS promoter is 
inserted between two insulators (5’ MAR of chicken lysozyme gene) to prevent 
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silencing effects. This vector was used to transfect primary porcine adult male 
fibroblasts (PAFs), thus obtaining transgenic cell colonies to use as nuclei donor in 
SCNT procedures. After SCNT, SOD1G93A embryos were transferred in recipient 
sows, and four pregnancies developed to term.  
Five piglets survived artificial hand raising, weaning, developed 
normally and reached adulthood. The remaining piglets died within 48–96 h after 
farrowing due to events commonly reported in commercial herds (i.e. neonatal 
diarrhoea or pneumonia, etc). Fibroblasts obtained from ear biopsy of living 
piglets were analyzed by immunocitochemistry (ICC) and revealed the transgenic 
protein expression. Furthermore Western Blot (WB) and immunohistochemistry 
(IHC) analysis were performed on dead piglets tissues, that proved to be all 
positive for the transgenic protein presence. Immunohistochemistry revealed 
granular mutant protein aggregates in the CNS.  
Unlike rodent models that show an extremely high expression transgene level and 
a rapid disease course [Turner & Talbot, 2008], our swine model presents an 
expression level comparable to that of human patients, where a single allele 
mutation results in a toxic gain of function. In rodents, the mutant SOD1 
expression level for a given mutation determines disease severity, higher levels 
yielding a more aggressive phenotype [Bento-Abreu et al., 2010]. However, since a 
SOD1G93A swine model has never been produced before, no data are available 
about the correlation between transgene expression level and disease onset timing 
and we can only make rough estimates as to when the first neurological symptoms 
may occur. Piglets are expected to show ALS symptoms in two or three years, 
while we cannot exclude a longer period. On one hand this could result in a longer 
pre-clinical phase and in an increase of animal maintaining costs, on the other 
hand our SOD1G93A swine could represent an invaluable opportunity to find early 
biomarkers and a closer and more faithful model to reproduce human pathology 
since ALS is typically an adult-onset disease. 
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Currently, an animal model recapitulating all the ALS crucial aspects 
has not yet been produced, although some transgenic mouse lines modulate a 
relatively faithful subset of disease features. However, since increasing difficulties 
are emerging in translating information gleaned from rodent models into 
therapeutic options for ALS patients, there is an urgent need for an intermediate 
research system.  
I do believe that a swine model could provide this essential bridge between 
insights gained from rodent models and the reality of treating a human disease.  
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1.1 OVERALL INTRODUCTION 
The existence of clinical conditions characterized by progressive 
muscular weakness and wasting became clearly recognized by the mid 19th 
century. In 1869 the famous French neurologist and physician Jean-Martin 
Charcot, studying the pathological features of this syndrome, described the 
characteristic alterations of the corticospinal tract and the loss of motor neurons 
and proposed the term amyotrophic lateral sclerosis [Charcot & Joffroy, 1869]. 
“Amyotrophic” refers to the muscle atrophy, weakness and fasciculation that 
derive from the degeneration of the motor neurons, whereas “lateral sclerosis” 
refers to the hardness to palpation of the lateral columns of the spinal cord in 
autopsy specimens, where gliosis follows degeneration of the corticospinal tracts. 
[Rowland & Shneider,  2001;  Silani et al., 2011].  The term motor neuron disease 
(MND) is commonly used in the United Kingdom to indicate the ALS syndrome. 
In the United States, ALS is often known as Lou Gehrig’s disease after the great 
baseball player who developed this disorder in the 1930s.  
Amyotrophic Lateral Sclerosis is defined as a progressive and fatal 
neurodegenerative disease resulting from the selective degeneration of upper 
motor neurons (UMNs) in the motor cortex and lower motor neurons (LMNs) in 
the brainstem and in the spinal cord (Figure 1.1).  
UMNs originate in the motor cortex and project to the spinal cord 
and LMNs connect the brain stem or spinal cord to muscle. When the motor 
neurons die, the nervous system becomes unable to initiate and control muscle 
movements. Because muscles no longer receive the input they need in order to 
function, they gradually weaken and deteriorate, producing deep atrophy.  
ALS is the most frequent of the motor neuron disorders, representing 85-90% of 
cases of this kind of pathologies. The majority of ALS patients present a sporadic 
form (sporadic ALS, sALS) but in 5-10% of cases the disease is inherited (familial 
ALS, fALS) [Mitchell & Borasio, 2007].  
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Regrettably, at the moment, no primary therapy for this disorder is available and 
the only drug approved for its treatment (riluzole) only slightly promotes 
survival; therefore symptomatic measures are the mainstay of management of 
ALS. 
Figure 1.1: The human Motor Neurons selectively affected in ALS. 
 
Degeneration of motor neurons in the motor cortex leads to clinically apparent signs of 
upper motor neuron abnormalities: overactive tendon reflexes, Hoffmann signs, Babinski 
signs, and clonus. Degeneration of motor neurons in the brain stem and spinal cord causes 
muscle atrophy, weakness, and fasciculation. [Adapted from Rowland & Shneider, 2001] 
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1.2 CLINICAL FEATURES OF ALS 
By definition, the features of ALS are signs and symptoms of lower 
motor neuron dysfunction associated with upper motor neuron dysfunction. LMN 
involvement determines weakness and fatigue, associated to progressive muscular 
atrophy, fasciculation (muscular twitching and shaking of contiguous groups of 
muscle fibers) and fibrillation (muscular twitching and shaking involving 
individual muscle fibers acting without coordination), reduced muscle tone and 
absence of tendon reflex. UMN involvement causes weakness, incoordination, 
stiffness and slowing of movement, with spasticity (persistent contraction of 
muscle), increased tendon reflexes, clonus (alternating contractions and 
relaxations) and extensor plantar responses. ALS probably begins a long time 
before its clinical manifestations, given that a substantial number of motor 
neurons can be lost before any clinical signs develop. In fact, several studies on 
animal models have shown that motor neuron dysfunction precedes the onset of 
symptoms and that compensatory reinnervation from nearby motor neurons 
permits a good maintenance of the motor function, although with an enlargement 
of motor units, until more than 50% of motor units have been lost; at this point 
symptoms appear and the number of motor units declines rapidly [Côté et al., 1993; 
Kennel et al., 1996]. 
No neuropathological, neurophysiological or biochemical markers 
are yet available to identify a patient as potentially susceptible for ALS prior to 
symptom onset. The different extent and localization of motor system involvement 
determines various early clinical features in different patients but ultimately, as 
the disorder progresses, the clinical expression of ALS is quite uniform, with 
extreme muscular wasting, spasticity and paralysis.  
At the onset, ALS presents with lower motor neuron involvement, upper motor 
neuron involvement or bulbar involvement. Limb onset is the most frequent, and 
is found in 75-80% of cases, while bulbar onset is evidenced in only 20- 25%.  
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The most common initial presentation of ALS is focal asymmetric distal weakness 
and muscular atrophy. For example, the patient may present himself with a 
history of unexpected tripping, dragging of a foot and ultimately more diffuse 
weakness of the leg.  Difficulty with buttoning clothes, turning keys in doors or 
simply poor coordination while performing fine movements are the symptoms of 
upper limbs involvement. Bulbar motor neuron degeneration leads to difficulty in 
swallowing (dysphagia) and speaking or forming words (dysarthria), associated 
to fasciculation of the tongue. Bulbar signs are often closely related to respiratory 
deficits, due to the involvement of diaphragmatic muscular weakness. This leads 
to a poor prognosis and to a shorter life expectancy.  
With the progression of the illness, the disease spreads to contiguous muscle 
segments. The progressive loss of motor function results in increasing disability 
and paralysis, ultimately leading to a bed-bound state. Recent findings have 
revealed that the selectivity of ALS for the motor system is not absolute. In fact, 
some reports describe cognitive impairment in a subgroup of ALS patients. A 
battery of neuropsychological tests has shown a cognitive impairment in about 
30% of ALS patients, ranging from mild impairment to frontotemporal lobar 
degeneration (FTLD).  
The main symptoms are executive dysfunction with deficits in verbal and non-
verbal fluency and concept formation [Lomen-Hoerth et al., 2003; Kilani et al., 2004; 
Abrahams et al., 2005; Schreiber et al., 2005; Rippon et al., 2006].  
However, in the majority of the cases, the rate of cognitive decline is very slow as 
compared to the devastating motor deterioration. Respiratory deficits, due to the 
progressive atrophy of respiratory muscles, appear during the progression of the 
disease. When respiratory muscle activity is insufficient, patients need to use 
mechanised ventilatory support. Respiratory failure finally leads to the death of 
almost all ALS patients without mechanised assistance. In 50% of cases the death 
occurs within three years from diagnosis. Table 1.1 includes all the main 
symptoms of the disorder. 
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Table 1.1: Symptoms attributable to ALS 
 
Direct (owing to motor neuronal degeneration) 
● Weakness and atrophy 
● Fasciculation and muscle cramps 
● Spasticity 
● Dysarthria 
● Dysphagia 
● Dyspnoea 
● Emotional lability 
 
Indirect (as a results of primary symptoms) 
● Psychological disturbances  
● Sleep disturbances  
● Constipation 
● Drooling 
● Thick mucous secretions 
● Symptoms of chronic hypoventilation 
● Pain 
1.3 DIAGNOSTIC METHODS FOR ALS 
Diagnosis of ALS is often critical, since many different clinical 
conditions may resemble this disease. To date, no test or specific marker can 
provide a definitive diagnosis of ALS; thus, it is primarily based on the symptoms 
and signs that the physician observes in the patient and on a series of tests to rule 
out other diseases.  
Implication of UMN and LMN signs that cannot be explained by any other disease 
together with a neurodegenerative process progression is suggestive of ALS.  
By The World Federation of Neurology (WFN) Research Group on Motor Neuron 
Diseases, criteria for clinical and pathological diagnosis have been defined during 
the ALS meeting held in El Escorial, Spain, in 1994 [Brooks, 1994] and updated at 
Airlie House, Virginia, four years later.   
Based on these criteria patients can be classified into “Clinically definite”, 
“Clinically probable”, “Clinically probable - Laboratory supported” and 
“Clinically possible” categories. Table 1.2 shows the essential features of the 
revised criteria.  The El Escorial scale classifies the probability of a patient having 
ALS according to the degree of clinical certainty in relation to other pathologies. It 
includes four degrees of certainty for the diagnosis of ALS.  
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Physical and neurological examination could detect UMN and LMN clinical signs 
in four regions (brainstem, cervical, thoracic or lumbosacral spinal cord) of CNS. 
The time required to confirm with certainty an ALS diagnosis from first symptoms 
is about 1 year [Chio & Silani, 2001; Borasio et al., 2001]. 
Table 1.2: Summary of revisited El Escorial criteria 
 
Definite  
Lower motor neuron and upper motor neuron signs in three regions 
Probable 
Lower motor neuron and upper motor neuron signs in two regions 
Probable with laboratory support 
Lower motor neuron and upper motor neuron signs in one region or upper 
motor neuron signs in one or more regions with EMG evidence of acute 
denervation in two or more limbs 
Possible 
Lower motor neuron and upper motor neuron signs in one region 
Suspected 
Lower motor neuron signs only in one or more regions or upper motor neuron 
signs only in one or more regions 
All categories need evidence of disease progression and absence of sensory signs not explicable on the basis of 
comorbidity. 
1.3.1 Electrophysiological Studies 
Electrophysiological studies primarily have the function of 
identifying LMN impairment and secondarily to exclude other pathologies. The 
revised El-Escorial criteria [Brooks et al., 2000] have proposed electrophysiological 
criteria for the diagnosis of ALS.  
By nerve conduction studies it is possible to define and exclude other peripheral 
nerve, neuromuscular junction or muscle disorders that may mimic ALS. F-wave 
studies are particularly useful in assessing proximal conduction and abnormalities 
that have been reported in ALS. To support ALS diagnosis is essential to provides 
by Concentric needle electromyography (EMG) evidence of LMN dysfunction in 
The Amyotrophic Lateral Sclerosis 
24 
at least two of the four regions of CNS: brainstem (bulbar/cranial motor neurons), 
cervical, thoracic, or lumbosacral spinal cord. The revised El-Escorial criteria 
delineate EMG evidence required for ALS diagnosis: signs of active or ongoing 
denervation and chronic partial denervation are needed, although relative 
proportions vary from muscle to muscle [Brooks et al., 2000]. Transcranial magnetic 
stimulation (TMS) allows a non invasive evaluation of the corticospinal motor 
pathways, and allows detection of UMN lesions in patients who lack UMN signs. 
Central motor conduction time (CMCT) should be marginally prolonged to 
muscles of at least one extremity in ALS patients. Motor unit number estimation 
(MUNE) is a electrophysiological method that can provide an assessment of axons 
number innervating a muscle or group of muscles, that may have role in ALS 
progressive motor axon loss assessment [Bromberg & Brownell, 2008]. 
1.3.2 Neuroimaging Studies 
In ALS diagnosis , the most important use of neuroimaging is to 
exclude treatable structural lesion that mimics ALS. Imaging studies are not 
required in cases of clinically definite disease with bulbar or pseudobulbar onset 
[Brooks et al., 2000]. Magnetic resonance imaging (MRI) can be used in revealing 
ALS lesions in the corticospinal tracts. The most characteristic finding in ALS is 
hyperintensity of the corticospinal tracts that is best visualised in the brain and 
brainstem [Goodin et al., 1988; Thorpe et al., 1996; Abe et al., 1997; Waragai, 1997]. 
Advanced neuroimaging modalities such as magnetic resonance spectroscopy, 
diffusion weighted imaging (DWI), diffusion tensor imaging (DTI), magnetic 
resonance voxel-based morphometry and functional imaging techniques (fMRI, 
PET and SPECT) do not have a use in routine diagnostics, but allowed to obtain 
promising results in the in vivo disease pathophysiology understanding, which 
may be realized in disease progression biomarkers identification and earlier 
diagnosis [Ellis et al., 1998, 1999; Turner & Leigh, 2000; Kalra & Arnold, 2003; Turner 
et al., 2004, 2009]. 
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1.3.3 Muscle biopsy and other laboratory studies 
For ALS diagnosis, skeletal muscle or other tissues biopsy is not 
required, but may be used to demonstrate LMN dysfunction when clinical or 
electrophysiological findings do not support this evidence. There are some 
laboratory tests that can be considered mandatory in the course of an ALS 
diagnosis, since they can be altered during this disease and include [Brooks et al., 
2000]: 
– muscle enzymes (serum creatine kinase [unusual above ten times upper limit of 
normal], AST (Aspartate transaminase), ALT (Alanine Transaminase), LDH (Lactic 
Acid Dehydrogenase); 
– serum creatinine (related to loss of skeletal muscle mass); 
– hypochloremia, increased bicarbonate (related to advanced respiratory 
compromise); 
– elevated CSF protein (uncommonly more than 100 mg/dl) 
1.4 EPIDEMIOLOGY OF ALS 
ALS is considered as a rare disease: it occurs in about 1-3 people per 
100,000 per year with a prevalence (number of surviving patients at any given 
time) of about 5-7 per 100,000. However, its personal and socioeconomic impact is 
greater and it has been calculated that its lifetime risk is approximately 1 in 1000 
[McGuire et al., 1996]. The frequency of ALS appears to have been rising 
moderately over the past 50 years. Although this rise may indicate the increasing 
effect of some unidentified exogenous factors, more probably it simply reflects the 
greater life expectancy of the population, which allows longer survival of a 
subpopulation susceptible to ALS.  
The average survival for sporadic ALS patients is approximately 3-5 
years after the first symptoms. Onset of ALS in patients younger than 50 years of 
age is generally associated with a longer survival.  
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The incidence of ALS increases with age [Kurtzke, 1991], with a peak 
occurring between 55 and 75 years of age; therefore, aging is the most significant 
risk factor. ALS occurs predominantly in males, with a male to female ratio of 1.4 
to 2.5; however, with increasing of age, this difference tends to diminish [Kurtzke, 
1991]. Environmental risk factors are inconsistently reported in ALS; this may 
reflect a complex interaction between several environmental risk factors and 
specific genetic susceptibilities.  
People of all races and ethnic backgrounds are affected by ALS and, with the 
exception of specific endemic areas in the Western Pacific, its worldwide 
frequency is uniform. Four geographic areas with a high prevalence 
(approximately 100-150 fold higher than the other regions) of ALS are described 
[Kurland & Molgaard, 1982; Oyanagi & Wada, 1999]: 
• Guam and Rota islands 
• 2 areas in the Kii peninsula 
• Irian Jaya (Indonesia) 
• Area of the Gulf of Carpentaria (North Australia) 
These geographic areas with an apparently higher prevalence of ALS have long 
been a source of interest to epidemiologists. Although familial ALS is almost 
indistinguishable from the sporadic form in terms of clinical phenotype, some 
features differentiate it from an epidemiological point of view [Mitsumoto et al., 
1998]. The average onset of fALS cases is approximately 47 years, a decade earlier 
than the sporadic type, and the mean survival is shorter; moreover, it occurs 
equally in males and females. Finally, in fALS, symptoms more frequently begin 
in the lower extremities compared to sALS. 
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1.5 NEUROPATHOLOGY OF ALS 
Immunohistochemical and ultrastructural studies performed on post 
mortem tissues of ALS patients have helped to better describe the neuropathology 
of the disease. However, post-mortem examinations are conducted on tissues 
representing the final stage of the pathology; thus the alterations observed reflect a 
very advanced state of neuronal degeneration and give little information about the 
triggering events causing the cell death. It is also true that patients have different 
degrees of neuronal degeneration in various areas of their central nervous system; 
for example, many patients with aggressive form of bulbar onset ALS at the time 
of death often have relatively spared motor neurons in the spinal cord. 
1.5.1 Motor system pathology 
The major pathological features of ALS are: 
I. Upper motor neuron abnormalities 
II. Myelin pallor in the corticospinal tracts 
III. Reduction in both size and number of LMN in the spinal ventral 
horns and in the bulbar nuclei. 
I. UMN involvement  
Upper motor neurons are defined as the neurons, localized in the motor cortex, 
that exert supranuclear control over LMN. The degree of degeneration observable 
at autopsy in the motor cortex of ALS patients is quite variable and may not be 
always evident, even in the presence of clear UMN signs. In the most severely 
affected cases, an evident loss of giant Betz cells in cortical layer 5, associated with 
an extensive astrogliosis and microgliosis, is reported. Since there are not good 
markers to distinguish UMN and other pyramidal cell types in the cortex, the 
identification of the Betz cell is often based on morphological and size criteria. 
Neuron cell bodies appear atrophied, with shorter fragmented dendrites [Hammer 
The Amyotrophic Lateral Sclerosis 
28 
et al., 1979]. Intracellular alterations are rarely identified in the spared Betz cells in 
classical ALS; occasionally, ubiquitinated neurofilament inclusions are reported. 
Pathological changes are rarely evident in somatosensory cortex, prefrontal cortex 
and premotor areas [Kiernan & Hudson, 1991].  
II. Corticospinal tract alterations  
Axonal degeneration of the descending corticospinal tract results in clear 
demyelination of the tract. As a consequence, the spinal cord of ALS cases shows 
pallor with myelin stain. Corticospinal fibers also show marked axonal swelling 
and spheroids [Chou, 1992]. An extensive gliosis is present, causing the typical 
sclerosis of lateral spinal cord tracts. 
III. LMN involvement 
Loss of large motor neurons localized in the lower brainstem and in the spinal 
cord is clearly observed at autopsy. Shrinkage and atrophy of the cell body 
precede neuronal death [Kiernan & Hudson, 1991]; the phenomenon is associated 
with alterations of axon and dendrite structures, which become thinner [Nakano & 
Hirano, 1987].  
Certain motor neuron groups, such as those controlling eye movements and the 
Onuf’s nucleus of the sacral spinal cord (that regulates the pelvic floor 
musculature) are spared by the disease. The remaining motor neurons present 
several abnormalities, listed below. 
• Ubiquitinated inclusions:  
Ubiquitin-positive inclusions are frequently found in the susceptible LMN 
groups of the spinal cord and brainstem of most cases and are defined as skein-
like inclusions or Lewy body-like accumulations. The first are a specific hallmark 
of ALS whereas Lewy body-like inclusions are found also in other disorders. Both 
inclusions probably represent two different morphological stages of protein 
aggregation, from diffuse filamentous forms to dense and compact inclusions. 
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Besides phosphorylated neurofilaments and ubiquitin, Lewy body-like inclusions 
also contain cyclin-dependent kinase 5 (CDK5) [Nakamura et al., 1997]; dorfin, a 
RING finger-type E3 ubiquitin ligase, has also been found [Hishikawa et al., 2003]. 
Recently, the nuclear factor TDP-43 (TAR-DNA-binding protein 43) has been 
identified as a major component of ubiquitinated inclusions in sALS cases 
[Neumann et al., 2006]; TDP-43 is thought to function as a regulator of transcription 
and alternative splicing [Buratti & Baralle, 2001; Buratti et al., 2004; Mercado et al., 
2005]. 
• Bunina bodies:  
 Bunina bodies are described as small, eosinophilic, irregularly shaped 
inclusions localized in the soma of motor neurons; probably they have a lysosomal 
derivation [Sasaki & Maruyama, 1993]. At the ultrastructural analysis, they appear 
like electron-dense, amorphous structures surrounded by vesicles, endoplasmic 
reticulum (ER) fragments, lipofuscin granules and are shown to contain cystatin C. 
Bunina bodies are reported to be present in 30-50% of cases; since they are not 
described in other disorders, they seem to be specific for ALS. Their pathogenesis 
and their relationship to neurodegeneration have not yet been unravelled. 
• Hyaline conglomerate inclusions:  
 Hyaline conglomerate inclusions consist of large aggregates of 
phosphorylated and non phosphorylated neurofilaments associated with other 
“entrapped” cytoplasmic proteins and organelles [Leigh et al., 1989; Sasaki & 
Maruyama, 1991]. They have been identified in sporadic and familial ALS; 
however, they seem to be less specific for this pathology, since they have been 
found in other neurological disorders [Sobue et al., 1990]. 
• Globules and spheroids:  
 Phosphorylated neurofilaments are also found packed in axonal swellings 
in the anterior horns of ALS patients [Corbo & Hays, 1992; Toyoshima et al., 1998]. 
Spheroids are larger and tend to be localized in proximal axons and dendrites, 
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while globules are smaller and usually are more peripheral in the ventral horn. 
Both are presumed to represent focal abnormalities of axonal cytoskeletal 
regulation with a failure of axonal transport.  
• Diffuse somatic phosphorylation of neurofilaments: 
 Diffuse accumulation of phosphorylated neurofilaments has been 
observed in the perikarya of motor neurons, especially in sALS [Hirano et al., 1984]. 
• Golgi fragmentation:  
 Both UMN and LMN of ALS cases show signs of fragmentation of the 
Golgi apparatus that is dispersed into numerous small isolated elements 
[Mourelatos et al., 1994; Fujita & Okamoto, 2005]. 
• Mitochondrial alterations:  
In recent years, morphological alterations of mitochondria in the motor 
neurons of ALS patients have been observed. These include dense conglomerates 
of aggregates, dark mitochondria, swelling and vacuolization [Hirano et al., 1984; 
Swerdlow et al., 1998]. 
IV. Involvement of other cell types  
Remarkable morphological and neurochemical evidence demonstrates the 
proliferation and activation of the microglial and astrocytic populations in the 
areas characterized by motor neuronal loss [Kawamata et al., 1992]. The concept of 
selective motor neuronal death has been challenged by studies reporting the loss 
of small neurons in the spinal cord of ALS cases [Oyanagi et al., 1989; Raynor and 
Shefner, 1994]. Stephens et al., 2006 report that the morphometric examination of 
the lumbar spinal cord of sALS patients revealed a substantial loss of ventral 
interneurons in addition to motor neurons. Therefore, the interneuronal 
population may degenerate to a similar extent and contemporary with the motor 
neuronal one. 
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1.5.2 Non-motor system pathology  
Autopsy examination revealed in some patients alterations in extra-
motor regions of the CNS, such as in the sensory system [Hudson, 1981], substantia 
nigra and hippocampus [Wharton, 2003]. 
1.5.3 Non-CNS pathology  
Profound skeletal muscles atrophy is one of the earliest pathological 
changes in ALS patients [Mitsumoto et al., 1998]. Other alterations are reported in 
the skin, in which the collagen cross-linking results altered [Kolde et al., 1996].  
1.6 GENETIC OF ALS 
ALS is considered a multifactorial disease, with a complex 
interaction between genetic and environmental factors. As already explained, the 
majority of ALS cases are sporadic, while the 10% of patients have a positive 
familial anamnesis for motor neuron disease, generally with an autosomal-
dominant inheritance pattern, although recessive pedigrees have been described 
[Mulder et al., 1986]. To date, 12 gene defects have been reported to cause ALS 
(Table 1.3). The protein products of these mutated genes are: 
1.6.1 ALS1 - Cu/Zn Superoxide-Dismutase 1 (SOD1) 
The linkage of ALS1 to chromosome 21q22.1 was described in 1991 
by Siddique et al., and two years later, Rosen et al. (1993) described eleven disease-
associated mutations in the SOD1 gene, spanning 9.3 kb, that is composed of five 
exons and encodes for a 153 amino acid forming the Cu/Zn superoxide dismutase 
1 enzyme. This is the most common form of inherited ALS, accounting for about 
20% of all familial ALS forms and corresponding to 2-3% of all ALS cases.  
The SOD1 is a highly conserved, ubiquitously expressed, 
cytoplasmic proteins, that converts superoxide, produced as a by-product of 
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oxidative phosphorylation, to oxygen and hydrogen peroxide; it is very abundant, 
representing up to 2% of the soluble proteins of the brain [McCord et al., 1969].  
SOD1 is an homodimeric metalloenzyme, composed by two 32 kDa monomer, 
where each consists of an eight-stranded beta-barrel and binds a copper and a zinc 
ion [Getzoff et al., 1989]. To date, more than 140 different SOD1 mutations have 
been identified in SOD1 gene and are localized in all the five exons, with no region 
of the polypeptide escaping from disease-causing mutations; 114 of them result in 
amino acid substitution and are known to cause the disease, whereas six silent 
mutations and five intronic variants do not. Although most mutations are 
missense, 12 are nonsense or deletion mutations that produce a truncated protein 
[Andersen et al., 2003]. 
Table 1.3:  Genes implicated in Familial ALS. 
Type Onset Pattern Linkage Gene Protein 
ALS1 Adult AD/AR* 21q22.1 SOD1 Cu/Zn superoxide dismutase 
ALS2 Juvenile AR 2q33-35 ALS2 Alsin 
ALS3 Adult AD 18q21 unknown  
ALS4 Juvenile AD 9q34 SETX Senataxin 
ALS5 Juvenile AD/AR* 15q15-21 SPG11 Spatacsin 
ALS6 Adult AD** 16p11.2-q21 FUS/TLS Fused in sarcoma 
ALS7 Adult AD 20p13 unknown  
ALS8 Adult AD 20q13.33 VAPB VAMP-associatated protein B 
ALS9 Adult AD 14q11 ANG Angiogenin 
ALS10 Adult AD 1q36 TARDBP TAR DNA-binding protein 
ALS11 Adult AD 6q21 FIG4 PI(3,5)P(2)5-fosfatase 
ALS12 Adult AD/AR 10p15-p14 OPTN Optineurin 
ALS Adult AD/AR 7q21.3-q22.1 PON1-2-3 Paroxonase 
ALS Adult AD 2p13 DCTN1 Dinactin 
ALS Adult AD 9p13-p12 VCP Valosin-containing protein 
AD = autosomic-dominant; AR = autosomic-recessive. * Mutation p.D90A is transmitted AR in the 
main number of families. ** H517Q mutation is trasmitted AR 
The Amyotrophic Lateral Sclerosis 
33 
Figure 1.2 shows human SOD1 three-dimensional structure and some mutations 
that cause ALS. All mutations are associated with autosomal dominant fALS, 
except for D90A and D96N, which can cause both dominant and recessive ALS 
[Andersen et al., 1995; Robberecht et al., 1996; Orrell, 2000]. The most frequent SOD1 
mutation is A4V. Penetrance, clinical manifestations, age of onset, disease 
progression and survival vary greatly among specific mutations. For example, 
A4V and A4T are associated with an aggressive fALS type, [Aksoy et al., 2003], 
while slow progression over 10-15 years is reported for mutations such as G37R, 
D90A, G93C and G93V [Arisato et al., 2003].  
Figure 1.2: Position of some mutations in the 3D structure of human 
SOD1.
 
To date, there is no certainty about the mechanisms by which SOD1 
gene mutations cause ALS. It was initially proposed that the toxicity of mutated 
SOD1 was associated with the loss of superoxide dismutase activity, thus resulting 
in increased cellular levels of reactive oxygen species, oxidative stress, and 
neuronal death [Deng et al., 1993]. However, most of the mutated isoforms of the 
SOD1 gene retain their enzymatic activity; therefore it is impossible to establish a 
correlation between residual enzyme activity, clinical progression, and disease 
phenotype [Radunović et al., 1997].  
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The creation of transgenic mice expressing SOD1 with some of the 
mutations found in the human patients, which develop a motor syndrome similar 
to human ALS, showed that the catalytic activity is unchanged or elevated [Gurney 
et al., 1994; Ripps et al., 1995; Wong, 1995a; Bruijn et al., 1997). Furthermore, SOD1 
knockout mice do not develop spontaneous motor neuron disease [Reaume et al., 
1996]. Also, the expression of mutant SOD1 alleles in cell culture models induces 
apoptosis in neurons [Pasinelli et al., 1998]. In both in vitro and in vivo models, 
dismutase activity appears to be normal or elevated, suggesting the conclusion 
that SOD1 mutants acquire one or more toxic properties, irrespective of the 
amount of superoxide dismutase activity that each of them retains. The SOD1 
propensity to misfolding to form cytoplasmic aggregates has been demonstrated 
by many studies. For their part, aggregates may result in cell death through 
sequestering other proteins essential for neuronal survival, by ubiquitin / 
proteasome system blockage, by chaperones depletion, by disrupting 
mitochondria and cytoskeleton and / or interrupting the axonal transport. 
1.6.2 ALS2 - Alsin 
A new gene linked to a rare, recessively inherited form of ALS 
characterized by juvenile onset and slow progression has been identified in 2001 
[Hadano et al., 2001; Yang et al., 2001]. ALS2 variant is characterized by the 
predominance of facial and limb muscles spasticity.  
The disease locus was mapped on chromosome 2q33-35 [Hentati et al., 1994], 
encodes a 184 KDa protein named alsin, spans 83 kb of genomic DNA and is 
composed of 34 exons. At least 13 different ALS2 mutations have been described 
so far, the majority of which are frameshift deletions resulting in a prematurely 
truncated protein, or nonsense mutations.  
Alsin is a ubiquitously expressed protein, particularly abundant in 
neurons where it is localized to the cytosolic portion of endosomal membrane. The 
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aminoterminal region of alsin contains sequence motifs that are characteristic of 
guanine exchange factors (GEFs), involved in the recycling of a specific small G 
protein from its GDP-bound state to its GTP-state. The carboxyterminal half of 
alsin contains two further domains, which are similar to those of the Rho G-
protein family that modulates dynamic actin assembly.  
The function of alsin is not fully understood, but it is known that it acts as 
exchange factor for the small GTPase Rab5a in vitro [Otomo et al., 2003; Topp et al., 
2004], suggesting a possible involvement in the organization of the cytoskeleton 
and in vesicle trafficking. In addition, alsin can interact with the small Rho GTPase 
Rac1 [Topp et al., 2004; Tudor et al., 2005].  
Interestingly, alsin is also able to specifically bind to different mutant variants of 
SOD1 through the RhoGEF domain [Kanekura et al., 2004] and, in a cell culture 
paradigm, it has been shown to suppress mutant SOD1 toxicity. All the disease-
causing alsin truncation mutations are highly unstable [Hadano et al., 2001]; this 
has led to the hypothesis that the disease is caused by loss of activity of the 
protein. However ALS2 knockout mice do not develop motor neuron disease [Cai 
et al., 2005]. 
1.6.3 ALS4 - Senataxin (SETX) 
ALS4 is a rare slow progressive motor neuron disease, characterized 
from autosomal-recessive inheritance and juvenile onset.  
ALS4 was initially mapped on chromosome 9q34, and was later discovered to be 
caused by mutations in SETX gene [Chen et al., 2004]. The gene is composed of 26 
exons and encodes for the 303 kDa ubiquitously expressed protein senataxin.  
Senataxin contains a DNA/RNA helicase domain with high homology to human 
RENT1 and IGHMBP2 (immunuglobulin-μ binding protein 2), two proteins 
known to have roles in RNA processing. Missense mutations in the SETX gene 
lead to a distal limb atrophy and to a motor neurons loss so slow that the life span 
is not reduced. 
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1.6.4 ALS5 - Spatacsin 
ALS5 is an autosomal-recessive, juvenile-onset motor neuron disease 
characterized by distal muscle atrophy and weakness with bulbar muscles 
involvement. The disease has been mapped to a locus on chromosome 15q15- 21 
[Hentati et al., 1998].  
The identified variants are mostly frameshift mutations or nonsense substitutions. 
SPG11 gene, composed of 40 exons, encode for the protein spatacsin that contains 
four putative transmembrane domains, suggesting that spatacsin may be a 
receptor or a transporter. However, its physiological role is still unknown, 
although it is reputed to be involved in axonal transport [Salinas et al., 2008]. 
1.6.5 ALS6 - Fused in sarcoma / Traslocated in sarcoma 
The ALS6 locus is mapped on chromosome 16p12.1-q21 on pedigrees 
with autosomal dominant ALS [Abalkhail et al., 2003; Ruddy et al., 2003; Sapp et al., 
2003]. Recently novel variants in the FUS/TLS gene have been identified as the 
disease causing mutations [Kwiatkowski et al., 2009; Vance et al., 2009]. The overall 
mutational frequency is ~4% in fALS and ~1% in sALS [Chio et al., 2009; Corrado et 
al., 2010; Bäumer et al., 2010; Hewitt et al., 2010; Millecamps et al., 2010; Rademakers et 
al., 2010; Robertson et al., 2011; Waibel et al., 2010; Yan et al., 2010]. More than 30 
different mutations have been hitherto described, which are mostly missense 
substitutions and the rest are frameshift or nonsense mutations.  
The FUS gene, composed of 15 exons for a total of 9 kb, encodes a 
DNA / RNA binding protein which is normally found in the cell nucleus and is 
involved in cellular processes, such as genomic stability maintenance and 
transcription and splicing regulation [Law et al., 2006]. In CNS, upon the activation 
of glutamate receptors, FUS is involved in regulating mRNA transport towards 
the dendrites [Fujii et al., 2005]. The FUS protein is composed of an N-terminal 
transactivating domain, a central domain that contains both a RNA recognition 
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motif and a zinc finger motif, and a C-terminal region [Morohoshi et al., 1998], that 
contain the nuclear localization signal (NLS) [Zakaryan et al., 2006], where the 
majority of the identified mutations is clustered.  
Neuropathological examinations of patient’s tissues, harbouring 
FUS/TLS mutations, showed an increased cytoplasmic FUS staining, and FUS-
immunoreactive cytoplasmic inclusions in LMN [Kwiatkowski et al., 2009; Vance et 
al., 2009]. Moreover, also data gained from in vitro experiments support the 
evidence that the FUS cytoplasmic redistribution is a key event in inclusion 
formation and motor neuron toxicity: cell lines transfection with GFP-FUS mutant 
fusion protein constructs resulted in increased cytoplasmic localization compared 
to transfection experiments with wild-type FUS vectors. Thus, it has been 
hypothesized that FUS mutations may contribute to ALS pathogenesis through the 
formation of cytoplasmic inclusions and/ or the loss of the physiological nuclear 
functions of the protein.  
1.6.6 ALS8 - VAMP-associated protein B 
A single P56S mutation in the VAPB gene, encoding for the VAMP 
(Vescicle-associated membrane protein B) causes ALS8. The VAPB gene is 
composed of six exons and spans 57.7 kb.  
The VAMP is a ubiquitously expressed homodimer protein, 
belonging to the family of intracellular vesicle-associated/membrane-bound 
proteins that can associate with microtubules and, presumably, regulates vesicle 
transport. In particular, VAPB has been shown to act during the transport through 
the endoplasmic reticulum, Golgi apparatus and secretion. The P56S mutation 
dramatically disrupts the sub-cellular distribution of VAPB and induces the 
formation of intracellular protein aggregates [Nishimura et al., 2004]. The P56S-
VAPB forms insoluble cytoplasmic inclusions in neural and non-neural cell lines, 
by sequestering wt-VAPB [Suzuki et al., 2009]. Supporting this hypothesis is the 
observation that the silencing of the VAPB homologous gene in Drosophila 
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melanogaster leads to larvae progressive paralysis by cytoplasmic inclusions 
formation and subsequent neurodegeneration. The phenotype is rescued by 
overexpressing the human VAPB gene [Chai et al., 2008]. 
1.6.7 ALS9 – Angiogenin 
The hypothesis that some angiogenic factors may be involved in ALS 
pathogenesis is increasingly evident. Firstly is reported an association between 
two vascular endothelial growth factor gene (VEGF) promoter haplotypes and 
susceptibility to sALS. Moreover the down-regulation of VEGF expression leads to 
progressive motor neuron degeneration in mice [Lambrechts et al., 2003]. On the 
contrary, VEGF administration has neuroprotective effects and improves hSODG93A 
transgenic mice disease phenotype [Azzouz et al., 2004]. In 2004, a single point 
mutation in the ANG gene, encoding for a VEGF effector named angiogenin has 
been associated to sALS susceptibility [Greenway et al., 2004, 2006]. The ANG gene 
is located on chromosome 14q11 and is composed of two exons, of which only one 
is encoding, for a total length of 5.4 kb.  
Angiogenin protein is a member of the pancreatic ribonuclease 
superfamily and is mainly expressed in hepatocytes. After its secretion into the 
serum and the extracellular matrix, through uptaking by still unidentified 
endothelial receptors, angiogenin is translocated into the nucleolus where it 
stimulates tRNA transcription and protein translation [Moroianu & Riordan, 1994].  
The majority of the 15 mutations hitherto described is clustered in the catalytic site 
or into the nuclear import signal and are consequently predicted to disrupt 
angiogenin secretion, ribonucleolytic activity and/or nuclear translocation, 
consequently producing angiogenesis alteration [Wu et al., 2007]. Thus, the loss of 
angiogenin functions may lead to motor neuron degeneration. Moreover, the 
mutant protein damages neurite growth and appears to be toxic on motor neurons 
in vitro [Subramanian et al., 2007]. Lastly, administration of human recombinant 
angiogenin prolongs hSOD1G93A mice lifespan [Sebastia et al., 2009]. 
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1.6.8 ALS10 - TDP-43 
In 2006 by Neumann et al. was identified the 43-kDa TAR-DNA 
binding protein as the main component of ubiquitinated cytoplasmic inclusions in 
ALS where is hyperphosphorylated and cleaved to generate abnormal C-terminal 
fragments. In unaffected neurons TDP-43 is localized in the cell nucleus and, 
instead, is absent from the nuclei of neurons with ubiquitinated inclusions; this 
phenomenon suggests a variation of the protein distribution between the nucleus 
and cytoplasm. TDP-43 is a 414 amino-acids, multifunctional DNA/RNA binding 
protein, ubiquitously expressed in the cells nucleus, and composed of two highly 
conserved RNA recognition motifs (RRM1 and RRM2), flanked by an N-terminal 
domain and a C-terminal tail, containing a glycine-rich region involved in others 
hnRNPs interactions [Buratti et al., 2005]. The TDP-43 specific functions in neurons 
is still unclair, although it seems to play a role in several biological processes, such 
gene transcription, splicing regulation, transport and stabilization of mRNA 
molecules [Buratti & Baralle, 2008].  
To elucidate the TDP-43 pathogenic role in ALS are raised intense 
speculations: toxicity might be caused by TDP-43 aggregates that is sequestered 
away from its normal nuclear function or, conversely, that might have a 
independent toxic gain-of-function [Lagier- Tourenne et al., 2010; Strong, 2010; 
Ticozzi et al., 2010; van Blitterswijk et al., 2010].  
In 2008, Gitcho et al. and Sreedharan et al. independently reported that pathogenic 
mutations in the encoding TDP-43 gene, named TARDBP and located in 
chromosome 1, cause several neurodegenerative diseases such as fALS, fALS, and 
FTLD. The proposed mutational frequency is ~5% for fALS and 0.5-2% for sALS. 
To date, more than 30 different missense substitutions in TARDBP gene, all of 
them clustered in the C-terminal glycine-rich region that is encoded by exon 6. So 
far was not possible to establish clear genotype-phenotype correlation, since most 
TARDBP mutations are private. 
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1.6.9 ALS11 - PI(3,5)P(2)5-phosphatase 
In 2009, Chow et al. identified ten ALS-associated heterozygous 
mutations in the FIG4 gene, including substitutions and frameshift insertions and 
deletions. FIG4, composed of 23 exons, encodes for a 907-residue long 
phosphoinositide phosphatise that regulates the synthesis and turnover of 
phosphatidylinositol- 3,5-bisphosphate, a signalling lipid that mediates the 
retrograde transport of endosomal vescicles to the trans-Golgi network [Rutherford 
et al., 2006].  
1.6.10 Other fALS- associated genes 
Mutations in several genes involved in cytoskeletal stability and 
axonal transport have been suggested to play a role in ALS pathogenesis.  
Six deletions within the C-terminal domain of the NFH gene, 
encoding for the neurofilament heavy subunit, have been found in several sALS 
and fALS [Figlewicz et al., 1994; Al-Chalabi et al., 1999].  
ALS related mutations was also found in PRPH gene [Gros-Louis et 
al., 2004; Leung et al., 2004], encoding for peripherin, a neuronal intermediate 
filament protein involved in axonal outgrowth, which frequently detected in ALS 
patients motor neurons ubiquitinated inclusions [He et al., 2004].  
A single G59S mutation and three additional heterozygous missense 
mutations have been found in the p150 domain of DCTN1 gene, encoding for 
dynactin [Münch et al., 2004], a component of the dynein complex that is 
implicated in axonal transport. The mutation, which seems to affect the dynactin-
dynein motor microtubules binding, is dominantly transmitted and provokes an 
atypical motor neuron disorder characterised by vocal cord paresis. 
It is also been hypothesized that another group of candidate genes, 
involved in xenobiotics metabolism, may play a role in fALS pathogenesis. 
Organophosphorous compounds (OP), widely employed in agricultural and 
industrial fields, can disrupt the cholinergic transmission in the CNS and at 
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neuromuscular junctions. The covalent binding of OP to the neuropathy target 
esterase protein (NTE) leads to axonal degeneration in the spinal cord and 
peripheral nerves: mutations in the NTE gene have been associated with a 
progressive motor neuron disease [Rainier et al., 2008]. The paraoxonase enzymes 
(PON1, PON2 and PON3) represent the major detoxifying system for OP and are 
also involved in protecting cells against oxidative damage. Several studies have 
suggested an association between PON haplotypes and sALS susceptibility [Saeed 
et al., 2006; Slowik et al., 2006; Morahan et al., 2007; Landers et al., 2008]. A recent 
study identified eight mutations in the PON cluster in nine fALS and three sALS 
patients. However, to prove the segregation of these mutations with ALS, further 
studies will be needed to validate the PON mutations role in ALS pathogenesis. 
Tau is a member of the microtubule-associated protein family, which 
has the principal functions of stabilizing microtubules and promoting their 
assembly by binding to tubulin. In addition, tau is likely to regulate motor protein-
mediated transport of vesicles and organelles along the microtubules by 
modulating their stability [Sato-Harada et al., 1996; Ebneth et al., 1998]. In 
frontotemporal dementia with parkinsonism (FTDP), the mutation of tau gene 
affects the alternative splicing of exon 10, resulting in an excess of four repeat tau 
isoforms; this may cause a reduced binding of tau to microtubules in axons. No 
pure ALS case has been associated with tau mutations. 
1.6.11 Susceptibility genes 
Susceptibility genes are defined as genes that can potentially 
contribute to the development of ALS; in other words, mutations in these genes 
may lead to ALS interacting with other genetic or environmental risk factors.  
Among the genetic alterations that may confer a higher 
predisposition to the development of ALS, have been described mitochondrial 
DNA micro deletions encoding for cytochrome-C oxidase [Borthwick et al., 1999], 
RNA processing errors in the glutamate transporter EAAT2 (Excitatory Amino 
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Acid Transporter) [Lin et al., 1998], an abnormal copy number of the survival 
motor neuron gene [Corcia et al., 2002] and gene deletions of the chromosome 
5q13- linked neuronal apoptosis inhibitory protein gene [Jackson et al., 1996]. An 
increased frequency of the cytochrome P450 debrisoquine hydroxylase  allele, 
encoding a cytochrome P450 monooxygenase involved in drug metabolism and 
associated with a "poor metabolizer" phenotype, has been also reported [Siddons et 
al., 1996]. Frequently, these alterations were described in only few cases or the 
results of different studies are conflicting.  
Some evidence suggests that VEGF acts as a modifier of ALS in both 
human and mice. In a study conducted by Oosthuyse et al., ALS–like symptoms 
and neuropathology were observed in mice bearing a targeted deletion that 
eliminates the ability of VEGF gene to respond to tissue hypoxia [Oosthuyse et al., 
2001]. These mice show a normal baseline expression of VEGF, but have a 
pronounced deficit in the ability to induce it in response to hypoxia. The motor 
deficits appear between 5 and 7 months of age and gradually progress; various 
classical features of ALS are observed, such as accumulation of neurofilaments in 
the motor neurons, degeneration of motor axons and muscle atrophy. As regards 
to the human pathology, in a large European study three single nucleotide 
polymorphisms in the promoter region of the VEGF gene have been associated 
with an overall 1.8–fold increased risk of developing ALS. The promoter variants 
in the VEGF gene in these patients coincided with reduced levels of plasma VEGF 
[Lambrechts et al., 2003].  
Also neurofilament variants are probable modifying risk factors in 
sporadic ALS and may modulate disease expression. A set of small in-frame 
deletions or insertions in the repetitive tail domain of the large neurofilament 
subunit NFH has been identified in about 1% of 1,300 sporadic ALS patients 
examined [Al-Chalabi et al., 1999]. Although the known neurofilament sequence 
variants are not responsible by themselves of producing disease with high 
penetrance, it is likely that they are at least important risk factors for apparently 
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sporadic disease. The studies that link sALS to particular genetic variants so far 
known account only for a small number of the total cases; the causes could be a 
complex pattern of inheritance with very low penetrance, a high degree of 
heterogeneity and/or the existence of environmental factors predisposing to ALS.  
In conclusion, high genetic heterogeneity and complex interactions 
between genetic and environmental factors are the main obstacles in the process of 
the finding of new ALS genetic determinants.  
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Successful therapies for almost all diseases can only come from the 
understanding of cellular and molecular mechanisms that underlie their 
pathophysiology. With the aim to obtain insights into such mechanisms, the use of 
experimental models is essential. This is particularly true in case of diseases whose 
etiopathology is still unknown, which precisely ALS is. In general, such studies 
are carried out in vitro and especially in vivo because animal models reflect more 
closely the human diseases progression [Tovar y Romo et al., 2009]. 
2.1 IN VITRO MODELS  
2.1.1 Spinal cord cultures  
To study motoneuron characteristics, spinal cord primary cultures 
have been widely used [Ransom et al., 1977]. In general, because of their large size, 
motoneurons are relatively easy to identify in plated dissociated tissues, but 
unfortunately, they are under-represented and this leads to the necessity of using 
the motor neuron enriched cultures. Motoneuron enrichment could be achieved 
with cellular densities centrifugation followed by biochemical analyses of 
acetylcholine production [Schnaar & Schaffner, 1981]. Further purification of the 
motoneuron population can be obtained by flow cytometry.  
The disadvantages of modeling a complex disease such as ALS in 
such a limited system are obvious; in spite of this it was possible to draw some 
information such as, for example, the motoneurons vulnerability to glutamatergic 
excitotoxicity trough AMPA (2-amino-3-(5-methyl-3-oxo-1,2-oxazol-4-l) propanoic 
acid) receptors [Carriedo et al., 1996]. Moreover, this kind of studies have helped to 
elucidate the role played in ALS pathogenesis by micro and astroglia and other 
non-neuronal cell types, since accumulating evidence indicates that ALS is a non 
cell-autonomous disease.  
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2.1.2 NSC-34 cells 
Establishing an immortalized neuron cell line is a difficult task: to 
overcome this problem a hybrid neuroblastoma/ motoneurons cell line (NSC-34) 
was produced [Cashman et al., 1992]. Transgenic NSC-34SOD1 is considered a cellular 
model of ALS, since they exhibit some motoneuron alterations features as 
mitochondrial dysregulation [Raimondi et al., 2006] and Golgi fragmentation 
[Gomes et al., 2008]. 
2.1.3 Organotypic Cultures 
On plated cell cultures the majority of cellular interactions 
modulating the ALS processes, such motoneuron signalling as well as glia trophic 
support, are lost.  
To maintain intact tissue structures and its cellular interactions is possible to 
cultivate an entire spinal cord slice where neurons retain their metabolic 
characteristics [Delfs et al., 1989].  By organotypic cultures it has been verified that 
some neurotrophic factors protect motoneurons from excitotoxic death [Corse et al., 
1999; Tolosa et al., 2008]. As in cell culture, a major organotypic systems limitation 
is that they do not always carefully mimic what would be happening in vivo. 
2.2 IN VIVO MODELS 
One of the major breakthroughs in the field of ALS research derives 
from the development of animal models of disease that proved useful both for the 
study of pathogenetic mechanisms and to test potential pharmacological 
approaches. The study of experimental models of ALS is useful to investigate the 
triggering events occurring earlier in the pathology. Nowadays, many models of 
motor neuron degeneration have been discovered or developed. However, even if 
some of them are associated with gene mutations found in human ALS or 
considered risk factors for the disease, they recapitulate only some of the features 
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of the human disease. Nevertheless, these models may provide useful insights in 
deciphering the mechanisms of selective motor neuron degeneration as potential 
therapy targets. 
2.2.1 Spontaneous or Induced Models of ALS 
Mice carrying naturally occurring mutations on identified or 
unidentified genes provide animal models of motor system impairment, as 
recapitulated in Table 2.1. 
2.2.1.1 Wobbler Mouse  
The Wobbler mouse arose as the result of a spontaneous mutation at 
the “Institute of Animal Genetics” in Edinburgh [Mitsumoto & Bradley, 1982]. It 
shows a progressive forelimb weakness and atrophy, accompanied by a marked 
decrease of muscular strength and motor ability; the symptoms are associated 
with proximal axonal degeneration and vacuolar changes within the motor 
neurons of the cervical spinal cord with little involvement of the brain.  
The gene mutated responsible for this autosomal recessive this syndrome is 
VPS54, encoding a subunit of the Golgi-associated retrograde protein (GARP) 
complex involved in the transport of vesicles from endosomes to Golgi apparatus 
[Schmitt-John et al., 2005]. 
2.2.1.1.1 Nmd Mouse 
Mice showing neuromuscular degeneration, with autosomal 
recessive mutation localized on the gene coding for the ATPase/DNA helicase 
have been described [Cook et al., 1995; Cox et al., 1998]. Called Nmd 
(neuromuscular degeneration) mice, they present rapidly progressive hind limb 
weakness and motor neuron cell body degeneration and have a life span that 
range from 2 to 20 weeks.  
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Table 2.1:  Overview of spontaneous or induced mouse models showing 
motor neuron degeneration. 
Name 
Mutated 
gene 
Gene product Inheritance Human disease Reference 
Wobbler  VPS54  Subunit of the 
GARP complex  
recessive  NA  Duchen & Strich, 
1968 
Nmd  IGHMBP2  Immunoglobulin µ-
binding protein 2  
recessive  SMARD1  Cook et al., 1995 
MND Cln8 neuronal ceroid 
lipofuscinose 
dominant NA Ranta et al., 1999 
Pmn  TBCE  tubulin-specific 
chaperone E  
recessive  motor neuropathy 
HRD/SSS  
Schmalbruch  et 
al., 1991 
Wasted eEF1A2 translational 
elongation factor  
recessive NA Chambers et al., 
1998 
Loa  DYNC1H1  dynactin  dominant  Sensory 
neuropathy  
Rogers et al., 2001 
Cra  DYNC1H1  dynactin  dominant  sensory 
neuropathy  
Hrabé de Angelis 
et al., 2000 
SMARD: spinal muscular atrophy with respiratory distress, HRD: hypoparathyroidism-retardation 
dysmorphism syndrome, SSS: Sanjad-Sakati syndrome, and NA: not available 
 
2.2.1.1.2 MND mouse 
MND (motor neuron degeneration) is a spontaneous, dominant 
mutation localized to chromosome 8 in the coding region of the gene Cln8, 
belonging to the family of neuronal ceroid lipofuscinose-related genes [Ranta et al., 
1999]. MND mice exhibit an adult-onset, progressive deterioration of motor 
function with spastic paralysis moving from caudal to cranial spinal cord levels. 
They undergo a premature death at 10-12 months [Messer et al., 1987]. The number 
of choline acetyl transferase (ChAT) immuno-positive lumbar motor neurons is 
not different from normal mice [Mennini et al., 2002]. Neuropathological hallmarks 
are inclusion bodies containing ubiquitin, mitochondrial alterations, lipofuscin 
accumulation and neurofilament abnormalities. However, the presence of 
abnormal autofluorescent cytoplasmic inclusions rich in lipofuscin found in 
neurons, as well as in many other somatic organs, makes these animals a useful 
model for human neuronal ceroid lipofuscinosis rather than for ALS [Bronson et al., 
1993]. 
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2.2.1.1.3 Pmn Mouse  
The “Progressive motor neuronopathy” also known as “paralyse 
natural mutant” mouse carry a recessive point mutation on chromosome 13 
[Brunialti et al., 1995].  
Two groups identified the Pmn mutation as a Trp to Gly substitution at the last 
residue of the tubulin-specific chaperone E protein [Bommel et al., 2002; Martin et 
al., 2002], that is essential for the proper tubulin assembly and for the maintenance 
of microtubules in motor axons. Distal axonopathy with paralysis of the limbs and 
muscular atrophy are the most relevant clinical signs, while motor neuron cell 
bodies and proximal axons are relatively preserved [Schmalbruch et al., 1991]. 
Symptomatic phase begins at 2 weeks of age and evolves rapidly to death. 
2.2.1.1.4 Wasted Mouse  
It carries a recessive mutation on chromosome 2, in the gene coding 
for the translational elongation factor eEF1A2 [Chambers et al., 1998]. The symptom 
onset is around 2 weeks of age and the progression is very fast, leading to death 
within a month. Spinal and brainstem motor neurons are lost, while UMN are not 
affected [Doble & Kennel, 2000]. 
2.2.1.1.5 Loa and Cra Mice 
Two independent N-ethyl-Nnitrosourea-(ENU) induced mutagenesis 
experiments generated the mutant mouse lines: “Legs at odd angles” (Loa) [Rogers 
et al., 2001] and “Cramping 1” (Cra) [Hrabé de Angelis et al., 2000].  These animals 
show motor neuron disorders with substantial similarities to human pathology 
progression and features, such as ubiquitinated inclusions containing among other 
proteins mutated SOD1 and neurofilaments (NFs).  
Hafezparast and colleagues relate the Loa and Cra phenotypes two different 
dynein encoding gene point mutations [Hafezparast et al., 2003], thus supporting 
the hypothesis that disturbances in axonal transport lead to motor neuron loss. 
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2.2.2 Genetic Models of ALS 
The discovery of human mutations linked with ALS has made 
possible the development of etiological models in a wide variety of organisms, 
including nematodes, fruit fly, zebrafish and rodents. These transgenic systems 
had an important role in the understanding of the ALS pathophysiological basis.   
2.2.2.1 ALS1: Superoxide Dismutase 1 models 
SOD1 is ubiquitously expressed and protects from oxidative stress by 
converting superoxide to hydrogen peroxide. ALS-causative mutations in SOD1 
were initially thought to affect SOD1 superoxide dismutase activity, thus 
inhibiting its protective role against oxidative stress. However, SOD1 knockout 
mice do not develop ALS features, thus excluding the loss-of-function hypothesis; 
instead mutations in SOD1 cause a toxic gain of function [Ho et al. 1998; Reaume et 
al. 1996]. Table 2.2 recapitulated all the SOD1 models that have been hitherto 
produced.  
SOD1 Mice models 
Several transgenic mouse strains were created by the introduction of the sequence 
coding for human mutant SOD1 under the control of a promoter that enables 
ubiquitous expression of the transgene [Shibata, 2001]. The first ALS animal model 
has been created in the murine species: the fALS related SOD1 mutation, where at 
residue 93 a glycine is converted into an alanine (G93A), was expressed under the 
control of the human SOD1 promoter [Gurney et al. 1994]. In the following years, 
investigators have generated different lines over-expressing human SOD1 with 
G37R or G85R mutations [Dal Canto & Gurney, 1994; Wong et al., 1995a], or mouse 
SOD1 with G86R mutation [Ripps et al., 1995].  
These animals develop a phenotype resembling ALS, with an adult onset 
progressive motor paralysis, muscle wasting and reduced lifespan.  
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Table 2.2:  Summary of SOD1 animal models 
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Pathological changes mainly consist of depletion of motor neurons in the spinal 
cord, atrophy, gliosis, axonal swelling and presence of ubiquitin-positive 
inclusions. By contrast, mice overexpressing wild-type SOD1, generated by 
targeted gene deletion, remain clinically normal and do not develop motor 
phenotypes, consequently the SOD1 disruption alone seem to be insufficient to 
cause spontaneous motor neuron degeneration in mice. The mutant SOD1 
transgenic models are summarised in Table 2.2 and have been recently reviewed 
by Turner and Talbot (2008). In brief, ALS-like phenotypes of mutant SOD1 mouse 
models can vary according to mutation and transgene expression level. For 
instance, mice that express high or low amounts of the SOD1G93A transgene 
develop ALS-like phenotypes earlier or later, respectively, suggesting a mutant 
SOD1 dosage effect.  
Transgenic mice carrying 23 copies of human SOD1G93A are considered the 
standard model of ALS in therapeutic studies [Bendotti & Carri, 2004]. The model 
develops a motor system disease prevalently affecting lower motor neurons. 
Ultrastructural and microscopical analysis reveals that the earliest pathological 
sign in these mice is the vacuolization of large neurons in the anterior horns of the 
spinal cord [Bendotti et al., 2001]; it has been hypothesized that these vacuoles 
originate from the dilation of rough endoplasmic reticulum and from 
degenerating mitochondria. At the end stage, motor neuronal depletion is evident 
and hyaline, filamentous inclusions immuno-positive for ubiquitin and 
neurofilaments are present in some of the surviving neurons [Gurney et al., 1994; 
Migheli et al., 1999]. Transgenic mice expressing low levels of SOD1G37R mutant 
show a motor disease restricted to lower motor neurons, whereas higher copy 
number causes more severe abnormalities and affects a variety of other neuronal 
populations. The most obvious cellular abnormality is the presence in axons and 
dendrites of membrane-bounded vacuoles, which appear to be derived from 
degenerating mitochondria [Wong et al., 1995b]. Transgene expression of mutant 
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human SOD1G85R or its murine counterpart (SOD1G86R) develops a very aggressive 
pathology with a rapid progression to paralysis and death within two weeks from 
the first symptoms.  Differences on disease progression and survival in various 
SOD1 mutant mice depend on the mutation and the copy number of the 
transgene. The age of onset, the duration and several pathological features also 
vary in dependence of the mouse strain in which the mutation is expressed; this 
background effect suggests the existence of strong modifying genetic factors. 
SOD1 Rat models  
Two human SOD1 mutations have been modelled in rats: SOD1H46R and SOD1G93A 
(Table 2.2) [Howland et al., 2002; Nagai et al., 2001]. In these models, the onset of the 
disease occurs early and the progression is very rapid, directly proportional to 
mutant SOD1 expression. The SOD1G93A mutation causes a more aggressive 
disease in rats than the SOD1H46R mutation [Nagai et al., 2001]. Pathological 
abnormalities are similar to those observed in the mouse model with evidence of 
gliosis and vacuolization in both spinal cord and brainstem prior to clinical onset 
and motor neuron death [Howland et al., 2002]. These rat models offer the 
advantage of increased size, facilitating preclinical trials using intrathecal 
catheters.   
SOD1 Zebrafish models 
Expression of SOD1G93R transgene in zebrafish causes slow-progressing ALS 
phenotype with muscle atrophy, motor neuron loss, and reduced survival [Ramesh 
et al., 2010]. Age-dependent neuromuscular junction (NMJ) defects are also seen. 
However, denervation was not observed, which could be due to the regenerative 
capacity of zebrafish motor neurons [Reimer et al., 2008]. Further, the hSOD1WT, 
SOD1G93A, SOD1G37R, and SOD1A4V isoforms were used to produce zebrafish 
transgenic embryos: mutant but not wild-type SOD1, causes abnormalities in 
motor neuron axon [Lemmens et al., 2007]. Similar to rodent, these defects are dose-
dependent.  
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Drosophila and C. elegans models  
The expression of either human wild-type SOD1, or SOD1A4V and SOD1G85R 
mutations in drosophila models causes progressive deficits in climbing ability of 
transgenic flies; thus, human wild-type and mutants SOD1 forms are toxic to flies 
although motor neuron survival and life span are unaffected [Watson et al., 2008]. 
Motor neuron abnormalities might not translate to motor neuron loss due to the 
short life span of the fly.  
Several human SOD1 transgenic C. elegans strains have been created. Neuronal 
expression of human SOD1G85R causes locomotor defects and provokes mutant 
SOD1 aggregates formation, morphological defects in the ventral nerve cord 
processes, and dorsal cord synapses reduction. These animals do not experience 
motor neuron loss or reduced life span [Wang et al., 2009b].  
To analyse SOD1 aggregation, mutant human SOD1G85R, SOD1G93A, and SOD1G127X 
were expressed in C. elegans muscle where forms aggregates vary according to 
mutation [Gidalevitz et al., 2009]. 
2.2.2.2 ALS2: Alsin models 
Alsin knockout mice are generated by several research groups, [Cai et 
al., 2005; Hadano et al., 2006; Devon et al., 2006; Yamanaka et al., 2006] (Table 2.4) but 
these models do not present a well defined pathological motor phenotype, 
suggesting that, in mouse, alsin knock out is unable to provoke important motor 
defects. 
2.2.2.3 ALS6: Fused in Sarcoma models 
It is estimated that FUS/TLS mutations causes fALS in 4%-5% of 
cases. FUS/TLS deletion in mice causes postnatal mortality [Hicks et al., 2000] and 
until now mutant and/or wild type FUS/TLS transgenic models are no available.  It 
is hypothesised that mutant FUS/TLS induces the disease by a “gain-of-function” 
mechanism.  
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2.2.2.4 ALS8: VAMP-associated protein B models 
Recently transgenic mice expressing in the nervous system either 
wild-type or mutant (P56S) VAPB gene using a modified prion promoter were 
created [Tudor et al., 2010]. These mice do not develop motor phenotype and show 
no alterations in survival.  
2.2.2.5 ALS10: TDP-43 models 
Mutations in the TARDBP gene are rare and account for less than 5% 
of fALS. Various TDP-43 models have been hitherto created (Table 2.3) [Gitcho et 
al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki 
et al. 2008]. 
Mouse models  
To date, three research groups have created wild-type TDP-43 transgenic mice, 
expressing the TDP-43 gene under the control of Thy-1.2, CaMKII and mouse 
prion promoter (mPrp). Two groups express human TARDBPA315T from the mPrp 
while a third group expresses human TARDBPM337V from the mPrp; a fourth group 
expresses TARDBP without a NLS from the CaMKII promoter [Igaz et al., 2011; 
Shan et al., 2010; Stallings et al., 2010; Tsai et al., 2010; Wegorzewska et al., 2009; Wils et 
al., 2010; Xu et al., 2010]. The majority of these models were reviewed recently by 
Wegorzewska and Baloh (2011) that highlight the variation in phenotypes between 
models according to promoter and expression levels.  
Overexpression of TARDBPWT is toxic in almost all mouse models created. Both 
human and mouse TARDBPWT overexpression results in dose-dependent gait 
dysfunctions, tremors, paralysis, and eventually in premature death [Shan et al., 
2010; Wils et al., 2010; Xu et al., 2010].  
The CaMKII promoter mediated TARDBP expression provokes defects in learning 
and memory, as well as hippocampus and neocortex degeneration [Igaz et al., 2011; 
Tsai et al., 2010].  
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These findings have never been reported in patients where altered TDP-43 
expression has not been revealed. TDP-43 mislocalisation from the nucleus to the 
cytoplasm and subsequent aggregation is seen in ALS patients and might prevent 
normal nuclear TDP-43 function [Neumann et al., 2006].  
To investigate this possibility, Igaz et al. (2011) generated mice expressing human 
TDP-43 without NLS. TARDBPΔNLS mice have more aggressive neurodegeneration 
compared to TARDBPWT lines.  
Wegorzewska et al. (2009) generated mice expressing TDP-43A315T threefold higher 
than mouse endogenous one. These animals show gait alterations at about 13 
weeks, complete paralysis and die at ~22 weeks of age. Since in their experiment 
Wegorzewska et al. (2009) did not produce TARDBPWT mice, it was not possible to 
make a direct comparison between mutant and wild-type protein pathogenicity 
[Wegorzewska & Baloh, 2011].  
Stallings et al. (2010) generate mice expressing both TARDBPWT and TARDBPA315T: 
the TARDBPA315T animals present a more aggressive phenotype compared to that 
shown by Wegorzewska et al. (2009) mice. Even the TARDBPWT mice die 
prematurely although mutant TDP-43 appears more toxic than the wild-type form 
[Stallings et al., 2010]. Interestingly, high expression of hTDP-43 in rodents can lead 
to a down regulation of mouse endogenous one, suggesting that the protein auto-
regulates its expression. Thus, one hypothesis might be the loss on its self-
regulating ability to lead to the TDP-43-mediated neuronal death [Igaz et al., 2011; 
Xu et al., 2010].  
Kraemer et al. (2010), Sephton et al. (2010) and Wu et al. (2010) failed to generate 
Tardbp knockout mice, suggesting that TDP-43 is essential for embryonic 
development. Interestingly, Kraemer et al. (2010) reported muscle weakness in 
heterozygote Tardbp+/- mice. All of this data highlight two key points: the vital 
function of TDP-43 in development, and the effect of mutated TDP-43 levels on 
neuronal survival. 
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Table 2.3:  Summary of TDP-43 animal models 
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Rat models 
Both TARDBPWT and TARDBPM337V have been expressed in rats [Zhou et al., 2010a] 
under the control of the human TARDBP promoter. TARDBPM337V expression 
causes early mobility problems, paralysis, and death before pubertal age while 
rats expressing the TARDBPWT isoforms at comparable levels not develop motor 
phenotype thus suggesting that the mutant TDP-43 isoforms is more toxic than the 
wild-type one.  
Zebrafish models 
Two groups created zebrafish embryos expressing both human wild-type and 
mutant TARDBP mRNA. Laird et al. (2010) showed that mutant and wild-type 
TARDBP mRNA decreased axon length and increased aberrant branching. These 
defects were exaggerated with TARDBPA315T, and axonopathy severity was 
dependent on mRNA dose. Interestingly, mutant and wild-type TDP-43 localised 
to the nucleus, suggesting that cytoplasmic TDP-43 mislocalisation is not required 
for axonal defects [Laird et al., 2010]. Intriguingly, Tardbp knockout fishes present 
similar motor deficits and axonopathy that could partly be rescued by human wild 
type TARDBP mRNA expression, but not by mutant TARDBP, suggesting that 
pathogenic TARDBP mutations cause a loss of function.  Finally, the TDP-43 C-
terminal domain was shown to be required for pathogenicity in zebrafish [Kabashi 
et al., 2010]. Development of adult TDP-43 zebrafish should provide insight into 
how these motor defects manifest in adulthood. 
Drosophila and C. elegans models 
Knocking down endogenous TBPH, the Drosophila TARDBP ortholog, has proved 
deleterious to animal development by preventing the hatching from the pupal 
stage of the fruit flies majority. Animals reaching adulthood display dramatic 
motor defects such as an inability to fly/walk and reduced life span [Feiguin et al., 
2009].  
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Expression of either ortholog TBPH or human TDP-43 in Drosophila has had varied 
outcomes; however, a recurring theme is of wild-type and mutant TDP-43 
overexpression being pathogenic with dendritic branching increasing. Whilst 
aberrant dendritic branching is not seen in ALS, these studies further emphasise 
the neuronal specific toxicity caused by expression of wild-type and mutant TDP-
43, providing insight into its pathogenetic role. TDP-43 expression in eyes causes 
retinal degeneration, in mushroom bodies an age-dependent axonal loss and 
aggregate formation, whilst in motor neurons provokes axon swelling and motor 
neuron death [Li et al., 2010]. Thus, the action of TDP-43 toxicity might vary from 
cell to cell [Miguel et al., 2011]. 
Wild-type or mutant TDP-43 expression in C. elegans is also toxic. In the two 
transgenic C. elegans models created, the human TARDBP sequence is expressed 
under the snb-1 promoter control, causing animals to become uncoordinated. In 
one model, the number of GABAergic motor neuron synapses is dramatically 
diminished, and there is occasional axonal defasiculation [Ash et al., 2010].  
In the other model expression of pathogenically mutated G290A, A315T, or 
M337V TDP-43, in respect to the wild type isoforms, causes a more severe 
progressive locomotor defect and decreased life span [Liachko et al., 2010]. In 
mutant TARDBP animals there are early axonal abnormalities and GABAergic 
neurodegeneration. Interestingly, prevention of aberrant phosphorylation of 
mutant TDP-43 results in an amelioration of motor deficits, suggesting that TDP-
43 hyperphosphorylation is important in C. elegans pathogenesis. Knockout of tdp-
1, the TARDBP C. elegans ortholog, in contrast to what is seen in mice and 
Drosophila, does not cause obvious defects [Liachko et al., 2010], suggesting a 
slightly divergent role between TDP-43 and tdp-1 in development. This difference 
might relate to the absence of a glycine-rich C-terminal domain in tdp-1 of C. 
elegans. Transgenic studies in C. elegans, however, might point toward a greater 
conservation in neuronal function. 
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2.2.2.6 Models for rare fALS and candidate genes 
Dynactin 
The p150-glued is the largest isoform of the dynactin complex, whose 
physiological function is expressed by microtubules binding. Mutated isoforms of 
p150glued show a lower binding efficiency causing a “loss-of-function” [Puls et al., 
2003]. Moreover, it has been demonstrated, by in vitro studies on cell culture, that 
mutant p150gluedG59S causes protein aggregation [Levy et al., 2006]. It has been 
found that motor neuron loss in transgenic mice is caused by a dominant negative 
mechanism [Laird et al., 2008, Chevalier-Larsen et al., 2008]. Lai et al. (2007) 
generated a mutant p150GluedG59S knock-in mouse. Homozygous mice present 
embryonic lethality, while heterozygous ones develop motor neuron phenotype at 
10 months of age together with excessive accumulation of cytoskeletal and 
synaptic vesicle proteins at the neuromuscular junctions, loss of spinal motor 
neurons, increase of astrogliosis, and shortening of gait [Lai et al., 2007]. Mice 
overexpressing p150GluedG59S under the control of the neuron-specific Thy-1 
promoter was developed by Laird et al. (2008) and by Chevalier-Larsen et al. 
(2008) that observed a motor phenotype resulting in muscle weakness, paralysis, 
and eventually death (Table 2.4). 
Neurofilaments and Peripherin 
NFs consist of three subunits (NF-L, NF-M, and NF-H) and, attempting to 
determine their role in the pathology of motor neurons, over the years, a large 
number of transgenic mice with modifications related to NFs were made. 
Knocking out one of the NF subunits as well as simultaneously two of them does 
not provoke an obvious phenotype. Moreover, even the NFs subunit 
overexpression results in motor neuron death, though NF accumulations in 
neuronal cell bodies were found. However, the same NF-LL394P mutation causing 
the Charcot-Marie-Tooth disease, type 2E [Mersiyanova et al., 2000] in mice induce 
selective motor neuron death [Lee et al., 1994], although no effect on mouse life 
span was reported.   
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Peripherin is another intermediate filament, mostly expressed in the peripheral 
nervous system and upregulated after injury and by inflammatory cytokines.  
A frameshift deletion in the peripherin gene was discovered in ALS patients 
[Leung et al., 2004; Gros-Louis et al., 2004]. Transgenic mice overexpressing wild-
type peripherin develop a 2 years of age motor dysfunctions associated with 
motor axons loss and peripherin inclusion bodies appearance.  
The onset of this motor phenotype is accelerated by the absence of NF-L as shown 
by peripherin overexpressing/ NFL knockout crossbreed animals that also present 
a dramatic loss of motor neurons [Beaulieu et al., 1999]. 
Growth Factors 
Motor neurons survival depends on growth factors whose absence can cause 
neuron death. This is well illustrated by CNTF knockout mice, in which the ciliary 
neurotrophic factor gene is deleted and who develop with aging atrophy and 
motor neurons loss [Masu et al., 1993].  
Another example of this phenomenon is represented by VEGF knockout mice, that 
exhibit an adult-onset, slowly progressive motor neuron loss leading to muscle 
atrophy and a motor phenotype [Oosthuyse et al., 2001], despite the fact that these 
animals do not become paralyzed and have a normal life span. 
Tau 
Different transgenic mouse models over-expressing various human tau isoforms 
have been generated showing a clear motor phenotype [Spittaels et al., 1999; Zhang 
et al., 2004; Tatebayashi et al., 2002; Ramsden et al., 2005; Schindowski et al., 2006; 
Tanemura et al., 2002; Yoshiyama et al., 2007].  
These mice acquire an age-dependent CNS pathology, similar to FTDP, and show 
axonal degeneration in brain and spinal cord, progressive motor disturbance and 
behavioural impairment. In spite of these findings is not yet clear how tau is 
involved in ALS pathogenesis [Taes et al., 2010]. 
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Table 2.4:  Overview of mouse model for atypical or rare fALS and candidate 
genes. 
Disease 
Gene 
product 
Inheritance Animal 
Genetic 
modification 
Reference 
ALS2 Alsin Recessive Mouse KO(exon 3) [Cai et al., 2005] 
    KO (stop codon in exon 3) [Hadano et al., 2006] 
    KO (exon 3 and 4)  [Devon et al., 2006] 
    KO (exon 4)  [Yamanaka et al.,2006] 
ALS8 VAPB Dominant Mouse PrP; VAPB P56S  [Tudor et al., 2010] 
ALS  Dynactin  Dominant  Mouse  Knock-in G59S p150Glued [Lai et al., 2007] 
    Thy-1; G59 p150Glued [Laird et al., 2008, 
Chevalier-Larsenet al, 2008]
CMT2E/1F Neurofilament-L Dominant Mouse NF-L L394P [Lee et al., 1994] 
NA  Peripherin  NA  Mouse  overexpression  [Beaulieu et al., 1999] 
NA VEGF NA Mouse VEGFδ/δ [Oosthuyse et al., 2001] 
FTDP-tau  tau  Dominant  Mouse  4R human tau  [Spittaels  et al., 1999]  
    R406W human tau [Zhang et al., 2004, 
Tatebayashi et al., 2002] 
    P301L human tau  [Ramsden et al., 2005] 
    G272V, P301S human tau  [Schindowski et al., 2006] 
    V337M human tau  [Tanemura et al., 2002] 
    P301S human tau  [Yoshiyama et al., 2007] 
VEGF: Vascular endothelial growth factor, PrP: prion promoter, CMT: Charcot-Marie-Tooth, FTDP: frontotemporal 
dementia with parkinsonism, and NA: not available. 
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2.3 PATHOGENETIC HYPOTHESES IN ALS 
The current knowledge on disease mechanisms in ALS comes from 
the study of the effect of SOD1 mutations that provoke motor neuron disease 
through the acquisition of one or more toxic properties.  
Studies performed on human ALS autopsy samples or on SOD1 mutant mice have 
suggested the involvement of various processes as possible triggers or secondary 
events in ALS pathology.  
Thus, despite extensive research, the mechanisms underlining the motor neuron 
death still remain unknown, and, to date, most researchers consider ALS as 
multifactorial disease in which a complex interplay between multiple mechanisms 
including genetic factors, oxidative stress, excitotoxicity, protein aggregation, 
damage to mitochondria and axonal transport determines the motor neuronal 
death (Figure 2.1). 
2.3.1 Oxidative damage 
The role of oxidative stress as primary or secondary event in the 
pathogenesis of ALS still remains controversial.  
Increase in markers of oxidative damage has been reported in human patients 
affected by both sporadic and inherited forms of ALS [Beal et al., 1997; Ferrante et 
al., 1997; Liu et al., 1999] and in transgenic mouse models of the disease [Ferrante et 
al., 1997; Andrus et al., 1998]. 
However, in other studies, no significant differences in oxidative damage markers 
were found [Shaw et al., 1995; Bruijn et al., 1997]. Some studies suggested that a 
possible source of oxidative insult may be represented by the gain of toxic 
function of mutated SOD1 [Cleveland & Rothstein, 2001] that alters the enzyme 
activity through aberrant copper catalysis or improper metal binding. 
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Figure 2.1: Proposed mechanisms of toxicity in SOD1-mediated ALS.  
(A) Excitotoxicity is the hyperactivation of motor neurons resulting from 
failure to rapidly remove neurotransmitter glutamate from synapses due to 
deficiency in the glutamate transporter EAAT2 in the neighboring 
astrocytes. (B) ER stress is induced by abnormal interactions of mutant SOD1 
with ER proteins. (C) Proteasome inhibition due to “overload” of the 
proteasome degradation pathway with ubiquitinated misfolded protein 
aggregates may damage astrocytes and motor neurons. (D) Mitochondrial 
dysfunction mediated by mutant SOD1 deposition on the mitochondrial 
membrane provokes release of cytochrome c in motor neurons, whereas in 
astrocytes it leads to nitroxidative stress. (E) Toxic extracellular mutant SOD1 
is secreted from motor neurons and astrocytes after interaction with 
components of neurosecretory vesicles. (F) Superoxide production from 
microglia or astrocytes can damage neighboring motor neurons. (G) 
Altered axonal transport including an increase in retrogradely transported 
stress-related proteins was reported in mutant SOD1-expressing motor 
neurons. (H) Synaptic vesicle defects such as stalling and loss from distal 
synapse in vulnerable motor neurons is an early event in ALS. (I) Loss of tight 
junction proteins within capillary endothelial cells results in the disruption of 
the blood–spinal cord barrier and the occurrence of microhemorrhages 
within the spinal cord well before disease onset. 
 
[Adapted from Ilieva et al., 2009] 
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2.3.2 Mitochondrial dysfunction and apoptosis 
The mitochondrial involvement hypothesis comes from observations 
of morphological abnormalities such as mitochondrial swelling and vacuolation, 
in parallel with mitochondrial respiratory dysfunction in rodent models and ALS 
patients [Jung et al. 2002]. Since apoptosis is intimately linked with mitochondria, 
recent work into mitochondrial involvement in ALS [Sheridan & Martin 2010] has 
centred on mitochondrial abnormalities, mutant SOD1 association with 
mitochondria, and activation of apoptosis.  
Abnormal clustering and aggregation of mitochondria and membranous 
structures are observed in SOD1 and TDP-43 mouse models [Guo et al. 2010; Sotelo-
Silveira et al. 2009]. Wild-type and mutant TDP-43A315T mice display vacuolated 
mitochondria that cluster in dendrites and motor neuron axons. Therefore, 
abnormal mitochondrial morphology could affect mitochondrial function through 
cell-autonomous and non cell-autonomous mechanisms. Regarding the second 
hypothesis, embryonic astrocytes as well as embryonic motor neurons [Bilsland et 
al., 2008] expressing SOD1G93A display mitochondrial membrane potential 
reduction and intramitochondrial [Ca2+] increase. Zhou et al. (2010b) speculate that 
increased mitochondrial Ca2+ release in muscle could increase mutant SOD1 
aggregation causing a pathological feedback loop, resulting in defective Ca2+ 
signalling and muscle atrophy. Thus, dysfunctional mitochondria exist in motor 
neurons, glia, and muscle, all of which might influence motor neuron survival. 
2.3.3 Alterations of cytoskeleton and axonal transport 
The idea that cytoskeleton abnormalities may play a role in ALS 
pathology arises from early reports of neurofilament accumulations in the cell 
bodies and proximal axons of motor neurons of both sporadic and familial ALS 
[Hirano et al., 1984]. Subsequently, it has been shown that in mice the over-
expression of NF-H or NF-L subunits causes selective degeneration and motor 
neurons death [Côté et al., 1993; Xu et al., 1993], though it has not yet been clarified 
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whether neurofilament disorganization represents a secondary product of 
pathological processes or whether it directly contributes to the death of the motor 
neurons.  
In neurons, the transport of molecules and organelles is dictated by the highly 
polarized anatomy of these cells: axonal proteins are synthesized in the cell body 
and must be transported in an anterograde manner along the axons and dendrites 
to reach synapses, whereas substances such as peripherally located trophic factors 
must be transported centrally from the synaptic regions by retrograde transport. 
The molecular motors for anterograde and retrograde transport are kinesin and 
the dynein-dynactin complex, respectively. Several factors indicate that defects in 
axonal transport might contribute to the degeneration of motor neurons in ALS 
[Zhang et al., 1997; Borchelt et al., 1998; Williamson et al., 1999; Murakami et al., 2001] 
such as the demonstration that misfolded SOD1 inhibits fast kinesin-based 
anterograde transport [Bosco et al., 2010]. Moreover the identification of misfolded 
SOD1 in sALS patients without SOD1 mutations suggests that axonal transport 
damage could be a unifying ALS disease mechanism. 
2.3.4 Excitotoxicity 
Glutamate-induced excitotoxicity is considered another major 
mechanism that may contribute to the aetiology of ALS. An over-stimulation of 
neuronal glutamate receptors can cause neuron death by increasing the cytosolic 
free calcium thus overriding the storage abilities of mitochondria and ER and 
eventually activating the death cascades (Figure 2.1 A).  
The first indication of an involvement of glutamate-mediated excitotoxicity in ALS 
arose from studies showing increased levels of glutamate in the plasma [Plaitakis 
& Caroscio, 1987] and in the cerebrospinal fluid of a subset of ALS patients 
[Rothstein et al., 1990; Shaw et al., 1995]. It is likely that the regulation of AMPA 
receptors expression is related to motor neuron degeneration in ALS patients [Fray 
et al., 1998] and in SOD1 mutant mice [Bendotti et al., 2001]. 
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Figure 2.2: Contribution of mutant SOD1 within different cell types in ALS. 
Despite the apparent selectivity for motor neurons, multiple lines of 
evidence indicate that non-neuronal cell types contribute to pathogenesis 
and disease progression in SOD1-mediated neurodegeneration. Mutant 
SOD1 expression in motor neurons directs the onset and development of 
early disease, but does not influence its progression. In contrast, mutant 
SOD1 expression in microglia or astrocytes accelerates disease progression 
without affecting its onset. Expression of a dismutase-active mutant SOD1 
specifically in Schwann cells was found to slow disease progression, but the 
role of a dismutase-inactive mutant in these cells has not been tested. 
Mutant SOD1 expression within muscle or endothelial cells does not affect 
ALS onset or progression, although some reports suggest that muscle might 
be a direct target of mutant SOD1 toxicity. Lastly, the vasculature is 
damaged very early in disease, leading to loss of tight junctions between 
endothelial cells and microhemorrhages, but whether any of this is from 
mutant SOD1 within pericytes, the terminal astrocyte, or coming from cells 
outside the vasculature is not established. 1 [Ralph et al., 2005; Boillée et al., 
2006 b; Jaarsma et al., 2008], 2 [Beers et al., 2006; Boillée et al., 2006b; 
Wang et al., 2009c], 3 [Yamanaka et al., 2008], 4 [Lobsiger et al., 2009], 5 
[Holzbaur et al., 2006; Miller et al., 2006; Dobrowolny et al., 2008; Towne et 
al., 2008], 6 [Zhong et al., 2009].  
 
[Adapted from Ilieva et al., 2009] 
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2.3.5 Non cell-autonomous effects  
Recently, various evidence highlight the crucial role played by the 
cross-talk between neurons and non-neuronal cells, including microglia, 
astrocytes, skeletal muscle cells and immune system peripheral cells such as 
macrophages and T lymphocytes, in motor neuronal death induction (Figure 2.2).  
Firstly, the activation of either astrocytes or microglia a phenomenon named 
gliosis, is common to all ALS models including rodents and Drosophila SOD1 
models and TDP-43 rodents [Turner & Talbot 2008; Watson et al., 2008; Wegorzewska 
& Baloh, 2011].  
Secondly, motor neurons expressing mutant SOD1 did not degenerate if they were 
surrounded by wild type glia; reciprocally, wild type motor neurons surrounded 
by SOD1 mutated glia showed ubiquitin-positive inclusions [Clement et al., 2003].  
The importance of microglia for the pathological processes has been 
unravelled by experiments with deletable transgenes demonstrating that the lack 
of mutant SOD1 only in microglia and peripheral macrophages does not change 
the onset of the disease, but increases the survival [Boillée et al., 2006a].  
The implication of astrocytes and microglia in ALS has led to attempts to inhibit 
gliosis in order to delay disease progression. Replacing astrocytes, transplanting 
mesenchymal stem cells, and performing bone marrow transplants have all 
proved somewhat successful in either reducing gliosis and/or extending survival 
of SOD1G93A mice [Lepore et al., 2008; Ohnishi et al., 2009; Vercelli et al., 2008].  
Treatment with anti-inflammatory drugs such as minocycline 
reduces neuroinflammation and extends survival of SOD1G93A mice [Neymotin et 
al., 2009; Yang et al., 2010]. Following this work, a number of ALS patients sought a 
prescription for minocycline but unfortunately, with detrimental effect [Gordon et 
al., 2007].   
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2.3.6 Protein misfolding and aggregation 
Protein misfolding and aggregate formation are key features in ALS 
patients and other proteinopathies. Convergence of a possible common disease 
mechanism between sALS and SOD1-linked fALS was established recently when 
an aberrant wild-type SOD1 conformation was identified in sALS and fALS tissue 
not carrying SOD1 mutations [Bosco et al., 2010].  
It is unclear how protein misfolding or aggregate formation affects 
disease onset and progression or, indeed, what the mechanisms of SOD1 
aggregation are. Mutations in SOD1 (and potentially TARDBP) can affect protein 
folding, creating an alternate ‘‘misfolded’’ conformation that can associate and 
form aggregates, potentially through cysteine- mediated disulphide crosslinking 
[Karch & Borchelt, 2010].  However, it is uncertain which protein species are toxic: 
the misfolded monomers, misfolded oligomers, or insoluble aggregates.  
It is interesting to note that spinal cord homogenates derived from 
SOD1G93A mouse may promote aggregates formation in a prion-like fashion that, in 
turn, can penetrate cells and provoke aggregate formation [Chia et al., 2010; Münch 
et al., 2011]). If this phenomenon, observed in vitro, occurs also in vivo, it could 
explain the rapid ALS progression and the disease prion-like spread. In fact, at the 
beginning, the in vitro aggregates formation is slow, as the in vivo disease 
incubation period is, but later aggregates proliferate rapidly which, if translated in 
vivo, would result in widespread cellular toxicity and cell death [Chia et al., 2010; 
Münch et al., 2011; Ravits et al., 2007].   
Finally, it has also been hypothesized that proteasome activity could 
be inhibited by SOD1 aggregates, leading to accumulation of aberrantly folded 
forms of SOD1 and other proteins [Cleveland and Rothstein, 2001] (Figure 2.1 C).  
Cheroni et al. (2009) reported decreased proteasome activity in lumbar spinal 
cords of SOD1 mice: this finding suggests a vicious cycle in which protein 
aggregation increases misfolded SOD1 levels [Hoffman et al., 1996] and 
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simultaneously sequesters essential cellular components such SOD1WT within the 
aggregates, causing further cell damage [Bruijn et al., 1998].  
On the other hand, despite the TDP-43 aggregates prevalence in ALS patients, 
they are rare in TDP-43 models [Wegorzewska & Baloh, 2011], that invariably exhibit 
motor neuron degeneration or neuronal defects; thus, aggregate formation may 
not be required for TDP-43-induced neurodegeneration.  
2.3.7 RNA processing 
The discovery of the RNA binding protein TDP-43 in cytoplasmic 
aggregates of ALS patients and pathogenic TARDBP mutations in ALS suggests a 
role for RNA processing in ALS [Gitcho et al., 2008; Kabashi et al., 2008; Neumann et 
al. 2006; Sreedharan et al., 2008; Van Deerlin et al., 2008].  
Further highlighting the emerging role of RNA processing in motor 
neuron degeneration is the identification of causative FUS mutations in ALS, 
another gene encoding a RNA-binding protein [Kwiatkowski et al., 2009; Vance et al., 
2009]. Taken together, these observations suggest that a loss or alteration in 
normal RNA processing deleteriously affects motor neuron survival; however, it 
remains unclear which areas of RNA metabolism directly affect motor neuron 
survival. TDP-43 overexpression in mice causes a dramatic disruption of gene 
expression, suggesting an important role in transcriptional regulation [Igaz et al., 
2011]. Further, in times of stress, TDP-43 and FUS associate with stress granules, 
that likely regulate the stability of selected mRNAs [Anderson & Kedersha, 2006; 
Bosco et al., 2010]. If this process is altered by TDP-43 mislocalisation, aggregation, 
or loss of function, TDP-43 may be unable to dissociate from these granules, 
translation of key housekeeping proteins may be inhibited, and motor neuron 
function/viability may be affected. Combined with this is the defect in RNA 
metabolism seen in SOD1 mouse models in which protein translation is disrupted 
by increased levels of oxidised mRNA, presumably through increased oxidative 
stress [Chang et al., 2008; Volkening et al., 2009].  
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However, these studies only begin to identify the mechanisms potentially 
involved in ineffective RNA processing in ALS. The analysis and creation of 
further TDP-43 animal models, the expected arrival of new FUS animal models, 
and the creation of SOD1 animal models alternative to standard mice will allow 
the ALS research community to investigate this mechanism further. 
 
 
The swine as a model for Neurodegenerative Diseases  
 
 72 
 
 
 
 
 
 
 
THE SWINE AS AN ANIMAL MODEL  
FOR NEURODEGENERATIVE DISEASES 
The swine as a model for Neurodegenerative Diseases  
 
 73 
Animal models of human diseases have always played a central role 
in biomedical research for the exploration and development of new therapies. 
However, the evolutionary gap between humans and many of the applied animal 
models (eg rodents) has always prevented a direct applicability of the acquired 
knowledge to human therapy. In this regard, the pig model offers many 
advantages. Being a domesticated eutherian mammal, the pig has evolved in the 
same way as humans and represents a taxon with different selected phenotypes 
[Rothschild & Ruvinsky, 1998]. On the other hand, the pig also represents an 
evolutionary clade distinct enough from primates and rodents to provide 
considerable power in the understanding of genetic complexity, that is, how 
genetic variation contributes to diverse phenotypes and diseases.  
As outlined in Table 3.1 the swine has been used as a model for 
various aspects of human biology, thanks especially to its physiology, organ 
development and disease progression but also to the possibility of studying its 
organs using standard human technologies and to perform repetitive sampling of 
tissues. Detailed drug susceptibility testing is facilitated by large cell lines 
availability. In addition, the swine genome sequencing shows a high homology 
with the human one, also as regarding the chromosomes structure, thus allowing 
improvements of genetic and proteomic tools for pigs. On the basis of these 
numerous propitious aspects the swine allows a great number of biomedical 
researches and, in order to facilitate their handling for experimental purposes, 
several miniature strains have been created. 
2.3 TRANSGENESIS IN PIGS 
Transgenic animals can serve as models for many human diseases. In 
mice, the technology of homologous recombination in embryonic stem cells (ESCs) 
provides an ideal tool for modelling genetically based disorders. Nevertheless, the 
relatively short lifespan of mice and the genetic and physiological differences 
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between mice and humans makes the comparison and application of data between 
the two species quite difficult.  
Transgenic pigs can serve as an ideal biomedical model bridging this 
gap since they are physiologically closer to humans, have a longer lifespan than 
mice, and are easily bred in controlled conditions. The first genetic modification in 
pigs was accomplished through microinjection of hundreds copies of a foreign 
DNA into the pig zygotes pronuclei that resulted in the exogenous DNA and in 
the generation of the first transgenic pigs [Hammer et al., 1985]. 
Table 3.1:  Genetically Modified Pigs for Use in Biomedicine 
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This ability to insert new genetic material and/or subsequently delete or replace 
genes opened new possibilities for the use of pigs as a research animal. The 
medical community had already accepted pigs as an excellent model for surgical 
testing based on their respective organs similarity to human heart, coronary 
vasculature, liver, kidney, lungs, and brain [Swindle, 2007].  
The prospect of obtaining genetically modified pigs further extended 
their biomedical potential, especially to mimic inherited human diseases and to 
establish experimental DNA-altering treatments (i.e., gene therapy). Pigs are ideal 
for this type of genetic research as the size and composition of the porcine genome 
is similar to that of humans [Bendixen et al., 2010].  
However, for a long time, the only technique for creating transgenic 
pigs has been pronuclear injection of a gene construct [Uchida et al., 2001] (Figure 
3.1 A). DNA is microinjected into the pronuclei of zygotes collected from a super-
ovulated female, and then transferred to a recipient pig by embryo transfer 
[Hammer et al., 1985]. The technique is reliable and widely used, but only about 1% 
of injected eggs produce transgenic pigs [Niemann, 2004; Prather et al., 2008]. 
Moreover this method suffers from several drawbacks, the most serious being the 
random integration sites of the gene construct in the host genome, the lack of 
control over transgene expression levels, and differences in transgene expression 
in the offspring.  
Some alternative approaches addressing the above problems in 
transgenic pig production include sperm-mediated DNA transfer [Lavitrano et al., 
2002] (Figure 3.1 B) a technique which not been confirmed in later studies.  
An alternative method, oocyte transduction, uses a replication deficient virus to 
deliver the transgene to the porcine oocytes and can increase the percentage of 
transgenic offspring with seventy percent of piglets born carry the transgene DNA 
[Cabot et al., 2001]. By this technique a recombinant lentiviral vector is injected into 
the perivitelline space of one-cell porcine embryos (Figure 3.1 C).  
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Lentiviral gene transfer results in a high efficiency of transgenesis 
and, importantly, the transgene is transmitted through the germ line [Hofmann et 
al., 2003]. However, retroviruses undergo epigenetic modification, and retroviral 
expression is shut off either during embryogenesis [Jaenisch, 1976] or shortly after 
birth [Chan et al., 1998]. Moreover the use of lentivirus (HIV-1; EIAV) poses many 
safety and ethical concerns, due to the proven ability to activate oncogenes as well 
as the possibility of re-acquiring their pathogenic characteristics. These methods 
suffer of some limitations including the inability to pre-screen embryos for 
transgene integration prior to embryo transfer, the lack of expression specificity 
arising from random integration of foreign DNA, and the fact that only transgene 
addition is permitted, not deletion (i.e., gene knockout). Targeted introduction of 
transgenes and loss-of-function mutations via homologous recombination in ESCs 
has been used for genetic manipulation of mice for decades [Capecchi, 2000], but 
this method is not established in pig because of lacking of ESCs stable source.  
The most popular method of producing genetically modified pigs to 
date is through genomic modification of somatic cells followed by nuclear transfer 
(NT), first reported by Park et al. (2001) (Figure 3.1 D). In this process, the nuclei 
of somatic cells are transferred into enucleated metaphase II oocytes, and then this 
complex is activated by electrofusion. Reconstructed embryos are then cultured 
and transferred to synchronized recipients sows for gestation. The advantages of 
NT for gene transfer in pigs were described by Robl & First (1985), and nuclei from 
porcine blastomeres were used to produce the first cloned pigs from embryonic 
donor cells [Prather et al., 1989]. Soon after the demonstration that the nuclei of 
adult somatic cells could undergo proper reprogramming to produce viable 
mammalian offspring [Wilmut et al., 1997], the first cloned pig derived from 
differentiated cells (porcine fetal fibroblasts) was reported [Onishi et al., 2000] and 
was soon followed by the cloning of pigs from cultured adult granulosa cells 
[Polejaeva et al., 2000].  
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Figure 3.1: Methods available for the production of transgenic animals.  
(A) Pronuclear DNA microinjection: Recombinant DNA is injected into the male 
pronucleus of a one-cell porcine embryo. Injected embryos are cultured in vitro 
up to the blastocyst stage or directly transferred into surrogate mothers. (B) Sperm-
mediated DNA transfer: Linearized plasmid DNA is incubated with sperm. Sperm 
will internalize surface-bound DNA and can then be used for artificial insemination. 
(C) Viral oocyte transduction: The transgene transfected into a packaging cell 
line, and viral particles are collected. The virus is either injected into the 
perivitelline space between the zona pellucida and the zygote, or the zona 
pellucida is removed enzymatically, and the zona-free zygote is co-cultured with 
viral particles. The transduced embryos are transferred to surrogate mothers. (D) 
Somatic cell nuclear transfer: Somatic cells are transfected with the transgene 
and selected for transgene integration. The nuclei of transgenic cells are 
transferred into enucleated metaphase II oocytes. The activation of embryonic 
development is induced chemically or by electric current. The embryos are 
cultured up to the blastocyst stage in vitro and then transferred to surrogate 
mothers. 
 
[Adapted from Vodička et al. 2005] 
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Despite these achievements, NT is an inefficient process in pigs, as it does in all 
mammals without stably cultured ESCs. Many reconstructed pig embryos fail 
early in pregnancy, requiring large numbers of embryo transfers per recipient. The 
prevailing view is that incomplete epigenetic reprogramming of donor cell nuclei 
results in aberrant gene expression during development [reviewed in Zhao et al., 
2010]. Recently, some advances have improved the ability to genetically modify 
porcine donor fibroblasts to produce cloned transgenic pigs and by NT technology 
many useful disease models have been hitherto produced and are poised to have 
significant impacts in biomedical research.  
2.4 BIOMEDICAL APPLICATIONS  
2.4.1 Cell Tracking 
One of the first transgenic swine models is cloned animals expressing 
enhanced green fluorescent protein (eGFP) [Park et al., 2001; Lai et al., 2002b]. Since 
that time, pigs expressing multi-gene fluorescent proteins (red, blue, green, and 
yellow) have been produced [Matsunari et al., 2008; Webster et al., 2005]. Tissues 
obtained from such transgenic pig are employed in studies that require marked 
cells or organs. For example, fetal eGFP-porcine cells were used to evaluate the 
retinal progenitor cells survival after an allograft in wild-type recipient pigs with 
damaged retinas [Klassen et al., 2008]. 
2.4.2 Pig-to-Human Xenotransplantation  
The first landmark swine model derived specifically for human 
health was in the field of xenotransplantation. The urgent need for organs 
replacement is unmet by human organ donations, with over 110, 460 recipient 
candidates awaiting organ transplants in the United States [United Network for 
Organ Sharing, 2011]. The pig stands out as the most suitable donor for animal-to-
human xenotransplantation because of the similar size and physiological capacity 
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of its organs. Practically, however, the use of xenografted tissues of non-human 
origin faces many immunologic barriers. This has spurred a large scientific effort 
to make pig organs transplantable to humans.  
Rejection of pig organs by human recipients is caused by humoral 
and cell-mediated responses [reviewed in Klymiuk et al., 2010]. Hyperacute 
rejection (HAR) occurs within 24 hr of transplantation and results from antibody 
recognition of α1,3-galactose (α-Gal) epitopes synthesized by the enzyme α1,3-
galactosyltransferase (GGTA1). Acute humoral xenograft rejection (AHXR), 
usually begins after the first week of transplantation, and is caused by mismatched 
human leukocyte antigen (HLA) complex antigens that are present on all cells.  
To circumvent HAR, swine fibroblasts were produced with a knockout of the gene 
GGTA1. Production of cloned swine from these fibroblasts was a major victory in 
the search for human organ replacements [Lai et al., 2002a]. Antibody-initiated 
complement activation is one dominant mechanism through which AHXR occurs.  
Transgenic cloned swine that overexpress the complement 
regulatory protein human-decay accelerating factor (hDAF) and an enzyme that 
modifies α-Gal,N-acetylglucosaminyltransferase III have been developed to 
protect against AHXR and HAR, respectively [Fujimura et al., 2004]. Swine with 
multiple genetic modifications (e.g., GGTA1 knockout combined with hDAF 
overexpression) appear to be the most promising route to widespread availability 
of organs for human transplant. 
2.4.3 Cardiovascular Disease 
Swine are historically considered an excellent model for the human 
cardiovascular system [Turk & Laughlin, 2004].  
As a potential dietary source of essential and beneficial fatty acids, genetically 
modified pigs have been developed to express D12 fatty acid desaturase from 
spinach (Spinacia oleracea) [Saeki et al., 2004] to increase linoleic acid, as well as 
pigs expressing a humanized Caenorhabditis elegans gene, fat-1, encoding an n-3 
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fatty acid desaturase to increase the n-3/n-6 fatty acid ratio in meat [Lai et al., 2006]. 
These pig models can also be used to examine the cardiovascular effects of an 
altered n-3/n-6 fatty acid ratio in the swine themselves.  
Another important regulator of vascular health is the signalling 
molecule, nitric oxide (NO). Transgenic swine that overexpress endothelial nitric 
oxide synthase (eNOS) [Hao et al., 2006; Whyte & Laughlin, 2010], responsible for 
producing NO in the inner lining of blood vessels, will increase our understanding 
of the complex regulation of vasodilation and potential therapies for diseases 
related to endothelial dysfunction.  
These large-animal cardiovascular models will enable real-time 
measurement of functional parameters including blood flow, temperature, tissue 
oxygenation, perfusion and diffusion that are difficult or impossible to monitor in 
similar genetically modified rodent models. 
2.4.4 Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive disease [reviewed in 
Messick, 2010] caused by mutations in the gene encoding for the cystic fibrosis 
transmembrane conductance regulator (CFTR) anion channel. Symptoms of CF 
arise from faulty water and ion transport across epithelial tissues, leading to 
inadequate hydration of mucous secretions. Over 1,600 mutations related to CF 
have been described, and although several CFTR knockout mouse models have 
been developed, none of them develop the obstructive lung disease symptoms 
seen in humans [Bragonzi, 2010].  
In an effort to produce an accurate CF model, pigs were cloned from 
fetal fibroblasts in which the CFTR gene was mutated to produce null and CFDF508 
alleles [Rogers et al., 2008; Welsh et al., 2009]. These CF piglets display comparable 
defects, such pancreatic destruction and early focal biliary cirrhosis, to those 
occurring in newborn humans with CF [Meyerholz et al., 2010].  
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Recently, the CF pigs phenotype resolved a long-misunderstood question about 
the order of events in the inflammation/infection pathogenic cycle. The initial 
event displayed in CF pigs is impaired bacterial elimination from the lungs, 
followed by a cascade of inflammation and pathology [Stoltz et al., 2010]. This key 
finding about CF pathogenesis provides new options for CF therapy and 
prevention.  
2.4.5 Alzheimer’s disease 
Alzheimer’s disease (AD) is a progressive manifestation of dementia 
that typically begins with subtle failure of memory, gradually becoming more 
severe, and eventually, incapacitating the patient [reviewed in Avramopoulos, 
2009]. The familial, autosomal dominant AD (FAD) is correlate to Presenilins and 
APP (amyloid precursor protein) genes mutations, that are associated with 
increased production of proteolytic fragment Aβ which aggregates into fibrils and 
toxic oligomeric forms, initiating synaptic damage and neurodegeneration [Walsh 
et al., 2005].  
A genetically modified pig model for FAD was developed by Kragh 
et al., 2009. Porcine fibroblasts hemizygous (carrying a single copy) for a neuron-
specific splice variant of human APP were generated via transfection with a cDNA 
construct, followed by NT cloning. This splice-variant carries an AD-causing 
dominant mutation known as the Swedish mutation [Kragh et al., 2009]. The 
transgene was expressed in the brain, but the authors speculate that it may take 
until the age of 1–2 years before Aβ accumulates to symptomatic levels in the 
porcine brain [Götz & Götz, 2009] thus reflecting the typical human onset, that  for 
the majority (95%) of AD cases occurs in the adulthood.  
Pig models that address the genetic foundations of other forms of AD could 
provide translational data for early detection and new treatment in patients. 
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2.4.6 Spinal Muscular Atrophy 
Spinal muscular atrophy (SMA) is an autosomal-recessive 
neurodegenerative disease [reviewed in Prior, 2010]. Clinical manifestations of 
SMA include motor neuron loss and skeletal muscle wasting, which are 
consequence of deletion/mutation of the survival motor neuron (SMN1) gene.  
A highly conserved gene (SMN2) is also present exclusively in humans. Mutations 
in SMN2 have no clinical consequence if SMN1 is retained. In the case where 
SMN1 is mutated, the disease severity correlates inversely with SMN2 gene copy 
number, although SMN2 alone cannot prevent the disease.  
A recent porcine model for SMA was developed specifically to 
evaluate the efficacy, pharmacology, and toxicology of SMA therapeutics. This 
SMA porcine model is being produced in three stages: first, a knockout of the 
SMN allele produced SMN+/- pigs that, like their human SMN+/- counterparts, are 
phenotypically normal. Next, efforts are underway to introduce the human SMN2 
transgene into swine fetal fibroblasts to eventually generate SMN-/-/SMN2 pigs 
through breeding and a second round of nuclear transfer that will lead to 
completion of the pig model of SMA [Lorson et al., 2011].  
Effective SMA therapeutics do not currently exist, highlighting the value of a 
genetically modified pig model for this disease. 
2.5 THE USE OF SWINE IN NEUROSCIENCE 
Rodents and primates have been the preferred animal species 
studied within neuroscience. However the use of pig experimental models has 
increased dramatically, reflecting the considerable resemblance of pigs to human 
anatomy and physiology. Despite considerable progress in understanding 
neurobiological disorders, there are enormous efforts for refinement of knowledge 
about the neurobiological processes underlying normal and the abnormal human 
behaviour.  
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In this context, the use of swine as an alternative animal species 
could be appropriate for obtaining advanced understanding of general neuronal 
and behavioural processes.  
The potential for using pigs in paediatric brain research was recognized early 
[Glauser, 1966] due to the similarities in the extent of peak brain growth at the time 
of birth, the gross anatomy (i.e. gyral pattern, distribution of gray and white 
matter), and the growth pattern of neonatal porcine brain to that of human infants 
[Dickerson & Dobbing, 1966; Thibault and Margulies, 1998]. Subsequently, a 
substantial body of evidence has been gathered supporting the wider use of pigs 
rather than rodents for neuroscience research: through a literature search of the 
PubMed database using the keywords ‘‘swine brain animal model’’ it is possible 
to reveals four times as many hits in the period 1996–2005 than during the 
preceding 10-year period.  
2.5.1 The swine as a laboratory animal 
Agricultural pigs are most commonly used in research due to their 
ready availability and low price:  the most common breeds are Landrace, 
Yorkshire, Hampshire and Duroc [Bollen et al., 1999].  
The high body weight of mature animals, which can be as much as 300 kg, 
presents an obvious disadvantage. A reasonable alternative has been provided by 
the purpose-bred laboratory minipig, either the Yucatan or Hanford breeds, which 
have an adult body weight of 70–90 kg, or the Göttingen, Sinclair or Yucatan 
micropig breeds, which have an adult, final body weight of 35–55 kg.  
In experimental research, the use of inbred animals generally serves 
to diminish variability in the outcome data. Consequently, the number of 
experimental animals required to reject a null hypothesis can be minimized. 
Inbred strains of rodents have been available for decades, but such pigs are not 
widely available. Monkeys have never been inbred, and it is difficult to obtain 
homogenous and standardized groups of outbreed monkeys.  
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Thus, the availability of standardization and purpose-bred laboratory pigs is 
becoming increasing advantageous. Pigs have a long life span (12–15 years), are 
easily bred, produce large litter size and have a short gestation period (typically 
113–115 days) compared to monkeys. Young pigs grow fast, and normally attain 
puberty at 5–6 months for agricultural breeds, and at 3–4 months for mini and 
micropigs.  
In contrast to rodents, the prolonged period of porcine puberty may 
present advantages for studies of neurodevelopment and plasticity at the time of 
puberty. If compared to rodents, pigs require far more space for housing, and 
costly pig-specific housing facilities are required. However, housing costs of pigs 
are considerably less than for monkeys.  
Occurrence of infectious disease is an obvious detriment to any 
research study [Hansen, 2002]. However, enormous experience on the prevention 
and treatment of porcine infections, derived from agricultural experience, is 
readily available [Hansen et al., 1997].  
Pigs are easily anesthetized and moreover, using positive 
reinforcement training, pigs can be trained to accept intramuscular injections, 
change of dressing, without provoking excessive stress, or requiring fixation. For 
long-term drug infusion, and for prolonged electrophysiological recordings such 
as electroencephalography (EEG) pigs can be partially immobilized in a sling, 
which they can be trained to tolerate for several hours if the legs are freely 
hanging [Bollen et al., 1999]. 
2.5.2 In vivo brain experimental techniques 
Studies within the field of neuroscience encompass the use of a wide 
variety of applied scientific disciplines in order to assess neuroanatomical 
structures and neurochemical processes which constitute normal brain function, or 
which contribute to pathophysiology.  
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Much of the in vivo experimental instrumentation used for preclinical or clinical 
research has already been applied to pigs (e.g. PET, MRI, fMRI, EEG and EMG). A 
stereotaxic instrument and a brain atlas with stereotaxic coordinates, essential for 
the accurate implantation of electrodes and cannulae, and for the placement of 
injections, are available [Bjarkam et al., 2004; Watanabe et al., 2001]. 
The pig has proven to be a superior experimental animal for evoked potential (EP) 
recordings, a procedure that requires a relatively large brain. As a result, several 
functional mapping studies have been successfully performed in the pig brain 
[Craner & Ray, 1991a,b; Palmieri et al., 1987]. Basic principles developed for the 
earliest EP study of pig [Adrian, 1943] are still employed [Fang et al., 2005b, 2006; 
Okada et al., 1999]. Recently, it has also been possible to obtain EP scalp recordings 
in awake, non-sedated pigs [Arnfred et al., 2004].  
The pig has been used in a wide range of imaging studies for experimental models 
of traumatic brain injury [Duhaime et al., 2003; Grate et al., 2003; Munkeby et al., 
2004], Parkinson’s disease [Dall et al., 2002; Danielsen et al., 2000] and stroke [Sakoh 
et al., 2000, 2001].  
The size of the pig brain permits the identification of cortical and 
subcortical structures by conventional imaging techniques such as MRI [Jelsing et 
al., 2005; Watanabe et al., 2001] and PET (Figure 3.2). fMRI have recently been used 
to assess the development of the pig brain with respect to functional activity after 
somatosensory stimulation [Fang et al., 2005b, c, 2006], and in the course of 
postnatal myelination [Fang et al., 2005a].  
Thus, the pig has in recent years been usefully employed in studies encompassing 
the entire range of modern imaging techniques. 
2.5.3 Anatomy of the porcine brain 
Whereas the rat cerebral cortex is lissencephalic, the pig brain cortical 
surface more closely resembles human gyrencephalic neocortex [Hofman, 1985]. 
Similarities in the gross anatomy of pig brain to that of human brain has also been 
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demonstrated for the hippocampus, a limbic structure [Dilberovic et al., 1986; Holm 
& Geneser, 1989], as well as for subcortical and diencephalic nuclei [Felix et al., 
1999; Larsen et al., 2004], and brainstem structures [Freund, 1969; Ostergaard et al., 
1992]. The sulcal and gyral anatomy the pig brain has been described in detail in a 
number of studies [Craner & Ray, 1991b; Jarvinen et al., 1998; Jelsing et al., 2006b; 
Okada et al., 1999]. 
Figure 3.2: Structural MRI obtained in vivo from a young Danish Landrace 
pig on a Siemens 3 T scanner (A) and postmortem in a 4.7 T Varian scanner 
(B). 
 
[Adapted from Lind et al. 2007] 
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The extent and pattern of the cortical convolution pattern show similarities with 
carnivore gyrification [Myasnikov et al., 1994] (Figure 3.3).  
A number of neuroanatomical studies have been performed on the pig cerebrum 
including comprehensive descriptions of the allocortex and associated limbic 
structures [Kruska & Stephan, 1973], especially the hippocampus [Dilberovic et al., 
1986]. There have also been a number of functional/anatomical studies of specific 
cortical regions, e.g. occipital cortex, auditory temporal cortex [Plogmann & Kruska, 
1990], somatosensory cortices [Craner & Ray, 1991a, b], motor cortex and prefrontal 
cortex [Jelsing et al., 2006b].  
Figure 3.3: Schematic illustration of sulci and gyri patterns in the adult 
Göttingen minipig brain.  
Abbreviations: (1) cruciate sulcus; (2) diagonal sulcus; (3) coronal sulcus; (4) 
ansate sulcus; (5) lateral sulcus; (6) entolateral sulcus; (7) ectolateral sulcus; 
(8) suprasylvii sulcus; (a) anterior, (b) posterior; (9) sulcus naris; (10) 
ectosylvia sulcus; (11) sylvii sulcus; (12) rhinal sulcus; (13) praesylvii sulcus; 
(14) splenial sulcus; (15) cingulate sulcus; (16) longitudinal sulcus; (17) 
sagittal sulcus; (18) coronal sulcus.  
cereb., cerebellum; cor., coronal gyrus; diag., diagonal band of Broca; 
dienc., diencephalons; e.mar., ectomarginal gyrus; e.syl., ectosylvian gyrus; 
hyp., hypothalamus; mar., marginal gyrus; olf. b., olfactory bulbus; olf. tub., 
olfactory tubercle; sig., sigmoid gyrus; sup., superior frontal gyrus; syl., sylvian 
gyrus.  
 
[Adapted from Lind et al. 2007] 
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These studies have been based on cytoarchitectonics [Jelsing et al., 2006b; Kruska, 
1970], electrophysiology [Craner & Ray, 1991a, b], and neuronal tract tracing [Jelsing 
et al., 2006b]. 
The topology of the pig hippocampus, hidden within the temporal 
lobe, indicates a degree of encephalization lying between that of rodent and 
primate brain [Holm and West, 1994]. The topology of subcortical nuclei are 
available from stereotaxic atlases of the pig brain [Felix et al., 1999; Salinas-Zeballos 
et al., 1986] and from PET studies in which the distribution of dopamine receptors 
within the basal ganglia is delineated [Ishizu et al., 2000; Rosa-Neto et al., 2004].  
The pig brain striatum is similar to that of primates, but in contrast to 
the rat, is clearly divisible into a caudate and putamen, separated by the internal 
capsule. The thalamus, subthalamus and hypothalamic nuclei of pig brain have 
been described in detail, based both upon standard histological stained sections 
[Felix et al., 1999] as well as immunohistochemistry [Larsen et al., 2004].  
The hypo- and subthalamic nuclei have a high structural 
correspondence with the homologous structures in rat, non-human primate and 
man [Larsen et al., 2004], whereas the development of the pig thalamus seems more 
similar to that of primates.  
The cerebellum of pig has been investigated in relation to the 
organization of the cerebellar fissures, the deep nuclei [Riet-Correa et al., 2003], and 
the prenatal and postnatal development [Jelsing et al., 2006a]. Furthermore, 
cerebellum has been considered a key structure for investigations of brain growth 
[Pond et al., 1990), toxicology and comparative morphometry [Jelsing et al., 2006a]. 
The weight of the adult pig brain ranges from 80 to 180 g, depending 
upon adult body size, breed, as well as duration of domestication [Herre, 1936]. 
This weight is more than 50 times greater than that of rat brain, and is comparable 
to the brain mass of several non-human primate species used for experimental 
purposes.  
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The cortical convolution or gyrification is also more comparable to 
primate than that of rat. The total number of neocortical neurons is approximately 
430 and 325 million respectively in the Danish Landrace pig and in Göttingen 
minipig [Jelsing et al., 2006c]. In comparison, the total number of neocortical 
neurons in rat brain is 21 million [Korbo et al., 1993], versus the 19–23 billion 
neurons in the human cerebral cortex [Pakkenberg & Gundersen, 1997]. 
Compared with the young individual of rodents, carnivores, and 
other ungulates, the development of the neonatal pig including the brain appears 
in many respects to be more like that of the human newborn infant. The rate of 
intrauterine development of the fetal pig is similar to that of the human fetus, and 
the pig has consequently become the standard experimental model for human 
embryology and brain development. The pig brain growth spurt, like that of the 
human, seems to extend from late prenatal to early postnatal life [Jelsing et al., 
2006c; Pond et al., 2000], whereas the neurogenesis of rodents occurs almost 
entirely in the postnatal period. 
Furthermore, the maturation of the postnatal pig brain is comparable 
to that of humans with respect to myelination, composition [Mayhew et al., 1996; 
Thibault & Margulies, 1998] and electrical activity [Pampiglione, 1971]. 
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AIM OF THE THESIS 
 
The purpose of this thesis is the production of a swine model for ALS that will 
allow us to assess if this species may represent a more suitable model than the 
currently employed transgenic mice in recapitulating the disease. Therefore, the 
main objective is the birth of healthy piglet carrying the hSOD1G93A ALS related 
mutation, which was achieved through the following intermediate aims. 
The first aim is the production and characterization of ALS expression vectors, 
carrying the hSOD1G93A mutation, the most and best studied in transgenic rodents. 
The second aim is the production of swine hSOD1G93A transgenic fibroblast 
colonies (PAFG93A) to use in SCNT experiments. Then, I will assess the hSOD1G93A 
related effect on the early stage of embryo development, by in vitro culture of NT-
blastocyst. 
The third aim is the birth of transgenic piglets, in which the transgene expression 
will be verified.  
Finally, possible methodological approaches aimed at the clinical and phenotypic 
characterization of the ALS swine model will be identified, with particular regards 
to the comparative aspects between the knowledge coming from rodent models 
and those from human patients. 
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5.1 PRODUCTION OF ALS EXPRESSION VECTORS 
5.1.1 Vector construction 
The sequence homology analysis and the constructs design were 
possible thanks to the use of the VectorNTI-11 software (Invitrogen, Carlsband, 
CA). 
Restriction, modification (T4 polymerase and S1 Nuclease) and ligation (T4 ligase) 
enzymes have been purchased by Fermentas (Vilnius, Lithuania) and used as 
reported in their manual.  
The ligation products, obtained through the use of T4 ligase, were transfected into 
competent 1SHOT match1 CCDB survival E. coli cells (Invitrogen). The bacterial 
growth was performed on LB-agar medium (LB medium + 15g / l agar-agar), 
supplemented with the appropriate antibiotics, at 37° C overnight. The bacterial 
clones were grown in liquid medium, overnight at 37 ° C in 3 ml of LB medium 
inocula (10g NaCl / l, tryptone 10g / l, yeast extract 5 g / l, water up to volume) 
with an addition of the appropriate antibiotics (= Ampicillin 50 mg / ml 
Kanamycin 50 mg / ml and chloramphenicol 52 mg / ml), aliquoted in 13 ml 
ventilated sterile tubes. The mini preparation of plasmid DNA (miniprep) involves 
the alkaline lysis of the culture and the DNA precipitation by the addition of 0.9 
volumes of isopropanol to the supernatant obtained by centrifugation after 
inactivation of bacterial lysis.  
All plasmids used in molecular cloning steps were purified by an ion exchange 
columns kit NucleoBond PC 20 (Macherey-Nagel, Neumann, Germany). The 
water used in each procedure is microfiltered and sterile without nuclease.  
The Avantea research group has previously developed an ubiquitous eGFP 
expression vector, driven by the pCAGGS hybrid promoter (CMV-IE enhancer + 
chicken beta actin promoter) [Niwa et al., 1991] which is characterized by 
maintaining high expression level through the F1 generation of pigs [Brunetti et al., 
2008].  
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A Destination Vector pMGOrfA5’3’MARpuro5171 (Figure 6.1) was created 
inserting the Multisite Gateway system (Invitrogen) Conversion cassette (OrfA) 
into the ubiquitous expression vector.  
The resulting vector carried the pCAGGS promoter inserted between two 
insulators (5’ MAR of chicken lysozyme gene) [McKnight et al., 1992] to prevent 
various silencing effects (positional or copy number effects). The structure was 
also provided with a floxed, then removable using the Cre recombinase, SV40-
Puro cassette to select the transfected clones.  
By restriction of both pcDNA3.0hSOD1G93A and pcDNA3.0hSOD1wt plasmids 
(Figure 6.3 a,b) the BamHI/XhoI fragment of hSOD1G93A cDNA and hSOD1wt 
cDNA, respectively, was obtained. These fragments were inserted into the 
pENTRL1L2OligoSacISalI vector, obtaining either the “EntryClone” pENTRL1L2-
hSOD1G93A or the EntryClone” pENTRL1L2-hSOD1wt (Figure 6.5 a,b). 
On these vectors, by double digestion with the restriction enzymes SalI and 
BamHI, a deletion has been operated, in order to restore the open-reading frame, 
obtaining the pENTRL1L2-hSOD1G93AdelSB and the pENTRL1L2-hSOD1wtdelSB 
vectors respectively. These vectors are then used, after sequencing, in LR exchange 
reactions with the Destination Vector pMGOrfA5’3’MARpuro5171. Theses 
exchange reactions, mediated by the LR Clonase, were used to transform 
chemically competent E.coli cells (One Shot Mach1-Invitrogen).  
The resulting pMG5’3’MARPuro5171-hSOD1G93A and pMG5’3’MARPuro5171-
hSOD1wt vectors (Figure 6.8 a,b) were purified with Plasmid Mini Kit (Qiagen, 
Hilden, Germany), analyzed by different restriction enzymes, confirmed by 
sequencing and finally linearized by ApaLI (Fermentas). After phenol/chloroform 
purification, the vectors were precipitated and re-suspended in TE buffer. 
5.1.2 Cell isolation and culture 
Primary porcine fibroblasts cultures were recovered from adult male 
ear biopsy (pig adult fibroblasts, PAFs). Biopsy specimens were cut in small pieces 
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with a scalpel blade and the resulting tissue pieces were distributed on the surface 
of gelatin-coated dishes containing 1.5 ml of DMEM/TCM199 with 20% of fetal 
bovine serum (FBS). Culture medium was changed every 3 days.  
Cells were allowed to grow until they reached 50% of confluence. Tissue pieces 
were then removed and the cells sub-cultured until they reached confluence in 
DMEM/TCM199 with 10% of FBS and growth factors (βFGF). Growth conditions 
consisted of a 38°C temperature and of an atmosphere composed by 90% N2, 5% 
O2 and 5% CO2.  
Exponentially growing cultures were cryopreserved in DMEM/TCM199 with 20% 
FBS and 10% DMSO and stored in liquid nitrogen. These batches of cells were 
used throughout the following experiments. 
5.1.3 Fibroblasts Transfection with hSOD1G93A vectors 
The day before transfection, passage 3 PAFs were trypsinized, 
counted, and plated into 60-mm dishes in order to obtain about 1x106 cells at 80% 
confluency in 24 hours. On the transfection day, cells were trypsinized, counted 
and resuspended in 100μl of nucleofector solution (Basic Nucleofector Kit, Prim. 
Fibroblasts; Amaxa, Cologne, Germany), and mixed with 5μg of both 
pMG5’3’MARPuro5171-hSOD1G93A and pcDNA3.0hSOD1G93A   linearized vectors. 
Then PAFs and linearized vector were transferred into the nucleofection cuvettes 
and transfected with V-24 program (Nucleofector Amaxa).  
After nucleofection, cells were plated in 60-mm culture dishes containing fresh 
culture medium. After 24 hours, the drug (Puromycin: [1 μg/ml], G418 (Neomycin 
analogue): [1mg /ml]) employed in colonies selection was added. After 4 days (for 
puromycin) or 15 days (for neomycin), drugs-resistant colonies were picked up 
using 5-mm cloning discs and transferred into 24-mm well dishes. Cells were then 
expanded in DMEM/TCM199 with 10% FBS and 5ng/mL of βFGF at a temperature 
of 38.5°C and in a humified atmosphere containing 5% CO2 and 5% O2.  
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An aliquot was cryopreserved as described above, to be employed in nuclear 
transfer and the remaining cells were sub-cultured to perform expression analysis. 
5.1.4 Immunocytochemistry (ICC) 
Cells (transgenic hSOD1G93A PAFs and primary culture cells from ear 
biopsy obtained from transgenic piglets) were fixed with 4% PFA and then stored 
in phosphate buffer (PB) until analysis.  
In order to detect the expression of human SOD1 by ICC a rabbit polyclonal 
antibody (07-403 Millipore, concentration 1:200), directed against the full-length 
wild-type hSOD1 plus an N-terminal methionine is used. Unspecific binding 
blocking (10% goat serum) was followed by primary antibody incubation (RT, two 
hours). After 3 washes (PB with 0.2% BSA and 0.05% saponine, 3 minutes each) a 
secondary FITCH-conjugate antibody incubation (1 h at RT) was performed. 
Nuclei were counterstained with Hoechst (RT, 15’). After two washes slides were 
finally mounted in mounting medium (Citifluor).  
Human Umbilical Vein Endothelial Cells (Huvec) and wild type PAFs were used 
respectively as positive and negative controls.  
Fluorescence was detected by exposing fibroblasts to an epifluorescent light 
mounted on an inverted microscope (Nikon TE-DH100W) equipped with a FITC 
(for green) and DAPI (for nuclei) filter and with a digital imaging system (Nikon 
DIGITAL SIGHT DS-L1).  
Subjective assessment of transgene expression level was based on the comparison 
of the fluorescence intensity revealed in PAFs colonies with that of the controls. 
The negative control was assigned a Score=0 while the positive a Score=2, as 
showed in Figure 5.1. It should be noted that this is as subjective score attribution 
and values presented in this study are not objectively measured, neither absolute. 
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Figure 5.1: ICC on PAF colonies transfected with pMG5'3'MARPurohSODG93A 
vector 
[a] Human Umbilical Vein Endothelial Cells (Huvec) used as positive control, 
with score=2 of transgene expression level. [b] wild-type PAF used as 
negative control (score=0), [c] PAF clone 1D2 with score=1, [d] PAF clone 
1A1 with score=3, [e] PAF clone 2B2 with scores=4 and  [f] clone 2A1 with a 
score=6. DAPI is the filter used to highlight the Hoechs nuclear staining. 
FITCH allows the detection of the fluorophore conjugated with the 
secondary anti-rabbit antibody and then the transgene expression. MERGE 
is the overlapping of the two images. 
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5.2 PRODUCTION OF ALS PIGS 
5.2.1 Animal experimental procedures 
All procedures involving animals and their care are conducted in 
conformity with national and international regulations (EEC Council Directive 
86/609, OJL358, 1, 12 December 1987; Italian Legislative Decree 116/92, Gazzetta 
Ufficiale della Repubblica Italiana 10, 18 February 1992; and Guide for the Care 
and Use of Laboratory Animals, U.S. National Research Council, 1996) and after 
the approval of LTR-Avantea Local Ethic Committee. Yucatan Black PAFs were 
obtained from adult boar ear biopsy, coming from Italian pig farming. 
Subsequently PAF have been used in cloning procedures to obtain wild type pigs. 
Experimental pigs, born at the LTR facilities in Cremona, and raised there up to 
one year of age,are subsequently transferred and allocated at C.I.S.R.A. (Centro 
Inter-dipartimentale Servizio Ricoveri Animali) of the Faculty of Veterinary 
Medicine of Turin. 
5.2.2 Preparation of nuclear donor cells and SCNT 
Transgenic 1A1, 1A2, 1B1, 1C2, 1D1, 1D2, 1E2, 2A2, 2A6, 2B2, 2C1 
2C3 pMG5’3’MARPuro-hSOD1G93A and #C5 pcDNA3.0hSOD1G93A fibroblasts 
colonies were selected, as nuclei donors, according to uniformity and intensity of 
their expression level. 
The day before nuclear transfer, donor cells were induced into quiescence by 
serum starvation (0.5% FBS). 30 minutes before nuclear transfer, cells were 
prepared by trypsinization, washed and resuspended in SOF [Tervit et al., 1972] 
supplemented with 25mM HEPES (H-SOF).  
Ovaries with corpora lutea were collected at local slaughterhouse and carried to 
laboratory at 31–33°C. Oocytes were aspirated from follicles larger than 3 mm in 
diameter, washed, and transferred to maturation. DMEM-F12 supplemented with 
10% FBS, 110 μg/ml sodium pyruvate, 75 μg/ml ascorbic acid, 100 μg/ml 
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glutamine, 5μg/ml myoinositol, 0.4mM cystine, 0.6mM cysteamine, ITS liquid 
media supplement (insulin, transferrin, selenite, Sigma, 1μl/ml), gonadotropins 
(0.05 IU/ml FSH, and 0.05 IU/ml LH; Pergovet 75, Serono), 100ng/ml IGF1 
(recombinant insulin growth factor I analog), 50ng/ml EGF (recombinant 
epidermal growth factor analog), and 5ng/ml bFGF (human recombinant) was 
used as maturation medium. 
Oocytes were cultured at 38.5°C in 5% CO2 in humidified atmosphere. After 42 
hours maturation, oocytes were denuded of cumulus cells by vortexing in the 
presence of hyaluronidase in H-SOF and returned to maturation medium. Only 
oocytes displaying extruded polar body were selected. NT-embryos were 
reconstructed following a zona-free method [Lagutina et al., 2005, 2006; Oback et al., 
2003]. The zona pellucida of oocytes with extruded polar body was digested with 
0.5% pronase in PBS. The oocytes were washed in H-SOF with 10% FBS and 
returned to maturation medium. All the following manipulations were performed 
in H-SOF with 10% FBS. Zona-free oocytes were exposed to cytochalasin B 
(5μg/ml) and Hoechst (5μg/ml) for 5 min prior to enucleation. Metaphase 
chromosomes were removed under very short exposure to UV light with a blunt 
enucleation pipette.  
After enucleation, zona-free cytoplasts were individually washed for few seconds 
in 300 μg/ml phytohemagglutinin P in PBS and then quickly dropped over a single 
donor cell [Vajta et al., 2003] settled at the bottom of a microdrop of the diluted 
donor cell suspension. Forty-six to forty-eight hours after maturation onset, 
formed cell couples were washed in 0.3 M mannitol (Ca2+free, 100μM Mg2+) 
solution, fused by double DC-pulse of 1.2 kV/cm applied for 30 μsec and returned 
to maturation medium. 2 hours later (after 48-50 hours of maturation), NT 
embryos were activated by double DC-pulses of 1.2 kV/cm for 30 μsec applied in 
0.3M mannitol solution, containing 1mM Ca2+ [Cheong et al., 2002] and 100μM 
Mg2+.  
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After activation, embryos were kept in culture maturation medium with 5μg/ml 
cytochalasin B for 4 hours. NT embryos were cultured in SOF supplemented with 
essential and nonessential amino acids and with 4mg/ml BSA (SOFaa) in a Well-
of-the-Well system (WOW) modification [Vajta et al., 2000]. During embryo culture 
half of the medium was renewed on day 3 and on day 5 with fresh SOFaa. 
5.2.3 Embryo transfer and farrowing 
Estrus was synchronized by feeding 12 mg of altrenogest (Regumate, 
Intervet, Peschiera Borromeo, Italy) per sow for 15 days and injecting 0.15mg of 
PgF2a (Dalmazin, Fatro, Ozzano Emilia, Italy) on the 15th day of regumate 
treatment and 1000 IU of hCG (Chorulon, Intervet) 96 hours after the last 
altrenogest administration. The SCNT embryos were transplanted to the sows 
uterus on day 5 of development. Embryo transplantation was performed 4 days 
after animals ovulation by midventral laparatomy and pregnancy was examined 
at day 29, 36, 50, and 62 by ultrasonography. A cesarean delivery was performed 
at 114th day of gestation. 
5.3 TRANSGENE INTEGRATION ANALYSIS 
5.3.1 PCR 
Genomic DNA from wild type and SOD1G93A swine tissues, was 
incubated at 55°C overnight with lysis solution (100 mM Tris HCl pH 8.5, 5 mM 
EDTA, 0.2 % SDS, 200 mM NaCl) plus 100 μg/ml of ProteinaseK/ (Promega, 
Madison, WI). The lysate was subsequently treated with phenol: clorophorm: 
isoamilalcool (25:24:1) to remove proteins and finally precipitated with 0.9 
volumes of isopropanol by centrifugation (10', 16.100 g) and washed with 500 μl of 
70%ethanol (5', 16.100 g). After ethanol removal, pellets were air dried, 
resuspended in TE buffer. Genomic DNA thus obtained was used in both 
Polymerase Chain Reaction (PCR) and Southern blot analysis. DNA quantification 
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was carried out using the fluorimeter Qubit (Invitrogen). The oligonucleotides 
design for PCR analysis was possible thanks to the use of the VectorNTI-11 
software (Invitrogen, Carlsband, CA). For PCR analysis the PX2 thermocycler 
(Thermo, Dreieich, Gremania), the polymerase GoTaq Flexi-(GoTaq Flexi-Enzime 
mix - Promega, Madison, WI) in the presence of dNTPs (0.2 mM each), MgCl2 
(1.25 mM) and oligonucleotides (1 mM each) were used. Briefly, 20 μl of reaction 
mixture [1.25mM MgCl2, 1μM Primer-Fw (ATGGACCAGTGAAGGTGTGGG), 1μM 
Primer-Rv (AGTGTGCGGCCAATGATGC), 0.2mM dNTPs, Buffer 1x, Taq 1U] were 
added to 5 μl of DNA and then used as template for amplification cicles [1x (94°C, 
2’’), 35x(denaturation: 94°C, 30’’; annealing: 65°C, 30’’; elongation:72°C, 20’’), 
1x(72°C, 7’)].  
5.3.2 Southern Blot 
As regards to Southern blot analysis, the SOD1-DIG probes labeled 
with digoxigenin were obtained by amplification using the DIG DNA Labeling 
and Detection kit (Roche), following the same cycling protocol used for PCR. 
Probes were then precipitated with absolute ethanol and finally resuspended in 
sterile ultrafiltered water. 10 μg of genomic DNA, extracted from hSOD1G93A 
swine, were subjected to restriction analysis with SalI + BglII (10U/μgDNA) 
enzymes and incubated overnight at 37° C. The next day samples were 
precipitated with 0.9 volumes of isopropanol by centrifugation (10', 16.100 g) and 
washed with 500 μl of 70%ethanol (5', 16.100 g). After ethanol removal, pellets 
were air dried, resuspended in TE buffer and eventually subjected to 
electrophoresis migration overnight at 15V plus 2h30’ at 25V in 0.7% agarose gel. 
DNA samples were then transferred by capillarity on modified nylon membrane 
(Hybond-N+, Amersham) under denaturing conditions (NaOH 0.4N, 5h). The 
membranes thus obtained were hybridized with the probe SOD-DIG (20ng/ml) at 
42°C overnight, and processed the next day (blocking of nonspecific binding, 
incubation with anti-digoxigenin secondary antibody conjugated with alkaline–
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phosphatase, with chemiluminescent substrate and signal detection) following the 
technical specifications of DIG Luminescent Detection Kit (Roche). Finally 
membranes were used to impress (3h) photographic plates BIOMAX (Kodak) that 
subsequently have been developed (5’) and fixed (10’) in darkroom using GBX 
(Kodak) chemical reagents. 
5.4 FOLLOW UP OF ALS PIGS 
Characterization will be performed by investigations on preclinical 
and symptomatic animals and will consist of clinical and neurological 
examinations, associated with anatomopathological, neurophysiological, 
biochemical and neuroimaging analyses. 
5.4.1 General clinical assessment  
Animals characterization includes evaluation of eventually occurring 
symptoms: swine health conditions and neurological phenotype will be assessed 
and serum will be periodically drawn to evaluate cellular/biochemical profile. 
5.4.1.1 General clinical examination 
Animals will be daily examined to assess their general health 
condition: food and water consumption, weight, feed conversion rate and 
stress/distress signs will be monitored. 
5.4.1.2 Neurological  clinical picture assessment 
Specific neurological examination will be monthly performed by a 
team composed of specialists in human and veterinary neurology and in swine 
behaviour. If neurological alterations are detected, such examination will be 
intensified once a week. 
5.4.1.3 Serological investigations 
Blood samples will be monthly collected and a complete cellular and 
biochemical profile will be performed. If pathological affections occur, further 
serological investigations will be set up on affected individuals. 
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5.4.2 Specific investigations 
A 3D Motion Capture system will be designed to evaluate swine 
locomotor function and its alterations. Moreover, neurophysiological and 
neuroimaging analysis will be employed to characterize ALS phenotype in the 
hSOD1G93A swine. 
5.4.2.1 Locomotor function assessment  
Gait and movement alterations will be analyzed: animals will be 
evaluated periodically in order to detect alterations in coordination, strength, 
endurance and balance. A specifically-designed 3D Motion Capture system will be 
developed to evaluate objectively the locomotion capability of the animals and to 
detect minimal and precocious gait alterations. 
5.4.2.2 Electrophysiological clinical picture  
In order to study neuronal damage induced by the mutated protein 
accumulation, the feasibility of electromyography application on living pigs will 
be evaluated. Custom-made electrodes and detection systems will be developed to 
test for the potentialities of superficial EMG techniques in the assessment of the 
neuromuscular function.  
5.4.2.3 Neuroimaging analysis 
MRI on the living pigs brain will be performed in a suitable facility 
during preclinical and clinical phase in order to define physiological and 
pathological aspect of the hSOD1G93A swine cortico-spinal tract. 
5.4.3 Proteomics 
The identification and quantification of plasmatic protein 
differentially expressed by transgenic swine and controls will be performed 
through a proteomic approach.  Definition of a set of candidate proteins that may 
act as mechanistic/ prognostic ALS biomarkers will be conducted. 
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5.4.3.1 Protein extraction from plasma 
Since plasma is a highly complex mixture of proteins/peptides with a 
high dynamic range, adequate separation of the sample will improve the success 
of MS-based proteomic analysis including the identification and quantification of 
proteins that are present at low levels. To this purpose, depletion of the most 
abundant plasma proteins will be performed to increase the detection limit of low-
abundance proteins. 
5.4.3.2 Proteins pre-fractionation 
Protein extracts will be run in triplicates on 1-DE gel electrophoresis. 
Each gel lane will be manually cut into 24 bands of equal height. Excised bands 
will be crushed into small fragments, processed, submitted to in-gel trypsin 
digestion and peptide extractions. The final sample will be referred as digest 
which contains all peptides recovered from the digestion of a single gel-band. 
5.4.3.3 Mass-spectrometry-based protein identification and quantification  
Aliquot of each digest will be directly analysed by liquid 
chromatography-tandem mass spectrometry (LC-MS/MS) with an LTQ Orbitrap 
XL™ interfaced with a 1200 series Agilent capillary pump. The MS/MS data from 
the 24 gel bands will be submitted to the search engine Mascot (Matrix Science, 
UK). Scaffold software (Proteome Software Inc., US) will be used to validate 
MS/MS-based peptide and protein identifications. Peptide and protein 
identifications will be accepted if they could be established at greater than 99.0% 
probability with at least two identified peptides.  
These filtering criteria establish a false positive identification rate of 0% for the 
proteome dataset based on the decoy database search strategy. Identified proteins 
will be quantified using spectral counts directly computed by Scaffold software. 
Estimation of differential protein abundance will be expressed as fold-change 
(ratio of the averaged spectral counts in transgenic pigs samples to the averaged 
spectral counts in the control samples). 
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5.4.3.4 Differential protein expression and pathways analysis  
Multivariate statistical analysis will be performed on proteomic data 
to find discriminating proteins and systematic variation sources unrelated to 
protein pattern. In order to map the differentially expressed proteins into 
biological networks and for functional interpretation of the protein data, an 
integrated data-mining platform such as MetaCore (GeneGo Inc., USA) will be 
used. Pathway and protein network analysis will allow for the identification of 
novel relevant biological entities, represented by proteins sets and for the 
discovery of highly significant pathways in the pathogenesis of ALS. 
5.4.4 Post-mortem analysis  
SOD1 aggregation and deposition pattern and histological lesion 
profile will be evaluated on stillborn piglets or in case of animals death. 
5.4.4.1 Tissue banking 
Ear biopsy was performed on all piglets, in order to obtain primary 
PAF cultures and subsequent cryopreservation to establish a cell bank from each 
individual piglet. Brain, spinal cord, peripheral nerves, muscles and organs were 
sampled from stillborn or euthanized animals. Tissue samples were both formalin-
fixed/paraffin-embedded (FFPE) and paraformaldehyde-fixed. After 24 hours, 
paraformaldehyde samples were rinsed 2 times in PBS and then exposed to 
growing sucrose concentrations in order to achieve cryoprotection. Finally, 
samples were kept for 30 minutes in a 30%sucrose: OCT [1:1] solution and then 
included in OCT, frozen in isopentane and stored at -80°C. Finally, a part of every 
tissue was snap-shot freezed in isopentane and stored at -80°C. 
5.4.4.2 Western Blot (WB) 
Cells (transgenic hSOD1G93A PAF and primary culture cells from ear 
biopsy obtained from transgenic piglets) were lysed using Laemmli buffer 1X 
containing β-mercaptoethanol (5%) and boiled for 10 minutes. Total protein was 
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quantified by Qubit fluorometer (Invitrogen) using the QuantIT Protein 
quantification kit (Invitrogen). Tissues obtained from stillborn piglets were 
homogenized (1:5 mg/ml) in lysis buffer (50mM Tris HCl pH8, 150mM NaCl, 5mM 
EGTA pH8, 1.5mM MgCl2, 10% anhydrous glycerol, 1% Triton, 100μg/ml 
(=0.57mM) PMSF). Protein quantification was performed by BCA Protein Assay 
kit (Pierce). Thirteen μg of each sample were loaded onto Glicine-SDS-PAGE (4-
12%) and electrophoretically separated for 45 minutes at 200V using the 
MiniproteanII chamber (Biorad). Blotting onto Immuno-Blot PVDF membrane 
(Biorad) was obtained after 1h at 100V using MiniproteanII electroblotter (Biorad) 
according to manufacturer protocol. The resulting PVDF membranes were 
subsequently processed following the instructions of the chemiluminescent 
detection system Lumi-LightPLUS Western Blotting Kit Mouse/Rabbit (Roche). 
Detection of transgenic target was achieved using either a polyclonal Antibody 07-
403 (1:1000 Millipore) or a polyclonal Antibody GTX 100659 (1:800 Genetex) that is 
specifically directed against hSOD1 region within amino acids 75 and 138, which 
is different between human and swine. Pig β-actin expression was detected using 
the mAb ab6276 (1:5000 Abcam). The treated membranes were finally exposed, 
developed and fixed. 
5.4.4.3 Immunohistochemistry (IHC) 
All FFPE tissues were analysed by IHC. After antigen retrieval (95° 
bain-marie for 20 minutes), sections were treated with 3% hydrogen peroxide in 
methanol for 10 minutes to block endogenous peroxidase. Sections were incubated 
in Normal Goat Serum for 20 minutes and then overnight at 4°C in the primary 
antibody (GTX 100659; 1:250) dissolved in PBS. Afterwards, sections were rinsed 3 
times in PBS and incubated with relevant secondary antibody (1:200) for 1 hour. 
After 3 rinses in PBS, sections were incubated with Avidin-Biotin Complex for 30 
minutes. DAB was used as revealing agent. Sections were counterstained with 
haematoxylin. Ubiquitine-immunoreactive misfolded protein was detected by the 
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same IHC protocol, but the antigen retrieval step, with a rabbit polyclonal 
antibody (Dako Z0458, 1:100). 
5.4.4.4 Immunofluorescence (IF) 
FFPE tissues were further analysed by double immunofluorescence 
in order to characterize SOD1 deposition pattern. After antigen retrieval 
(microwave oven in citrate buffer, pH 6,0), sections were washed three times in 
TBST. Sections were then incubated for two days at 4°C with the primary 
antibodies (SOD 1 [GTX 100659; 1:250] and NeuN [MAB377; 1:1000]). Afterwards, 
sections were rinsed in TBST and incubated with Alexa Fluor® (1:200) for 15 
minutes and observed with a Nikon Eclipse 80i microscope.    
5.5 hSOD1G93A SWINE LINE ESTABLISHMENT  
Various assisted reproduction techniques will be used to generate 
offspring from the transgenic founders animals available. 
5.5.1 Pig breeding 
5.5.1.1 Semen collection and banking  
Semen will be collected from transgenic founder male by manual 
stimulation or elettroejaculation, a procedure already widely employed in animals 
with locomotor deficits or in wild/zoo animals. Spermatozoa will be used to 
inseminate wt sows or to generate embryos, to be transferred in recipient sows, by 
in vitro fertilization or ICSI in order to generate a F1 offspring to be used to 
propagate and establish the ALS swine line. By inbreeding of animals obtained 
from the second and from the subsequent generations, an homozygous ALS swine 
line will be established. 
5.5.1.2 Artificial insemination and embryo production  
Depending on the seminal material quality and quantity, as minipigs 
produce smaller amounts of semen, artificial insemination of wild type sows or in 
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vitro fertilization techniques, ICSI included, will be employed to establish 
pregnancies to generate F1 progeny.  
As long as artificial insemination is concerned, commercial breed gilts will be 
synchronized using Regumate and hCG.  30 hours after hCG administration, gilts 
will be inseminated with fresh semen or, after sedation and general anesthesia, by 
means of a laparoscopic insemination with frozen semen. If scarce or low quality 
seminal material doesn’t allow insemination, in vitro fertilization/ ICSI will be 
performed. Oocytes, isolated from ovaries collected at the local slaughterhouse, 
will be matured in vitro for 40 hours and then subjected to in vitro fertilization or 
ICSI. Five days later, the resulting blastocysts will be transferred by laparoscope to 
the uterus of synchronized gilts. 
5.5.2 F1 characterization and back crossing 
Newborn piglets will be screened by PCR to identify the transgenic 
animals (50% of the offspring are expected to carry the transgene). Transgenic 
animals will be subjected to an ear biopsy to establish a cell line to be employed in 
ICC to assess transgene expression level and in cell-banking. At puberty, most 
promising females will be back crossed with their male siblings to bring the 
transgene to homozygosity and to stabilize the ALS swine line using animals with 
high expression levels. 
5.5.3 Re-cloning of the most promising phenotypes 
Animals displaying a promising or valuable phenotype, which could 
also be identified after death or sacrifice, will be regenerated by re-cloning by 
Somatic Cell Nuclear Transfer in order to increase the number of animals 
available. A cell line from every transgenic animal born will be conserved in a 
dedicated cell bank. 
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5.6 RESULTS COMPARISON WITH BOTH OTHER ALS 
MODELS AND PATIENTS 
Results obtained from the characterization of the hSOD1G93A swine 
will be evaluated in order to assess if the pig may be considered a suitable species 
in which ALS can be faithfully reproduced. Moreover our results will be 
compared with literature data both in other ALS model and in human patients in 
order to identify similarities and differences and eventually strong point of our 
swine model. As far as statistical analysis is concerned, the study design will be a 
single-blinded, randomized clinical trial. 
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6.1 VECTOR CHARACTERIZATION 
On the following pages both graphical representations and 
restriction analyses of vectors realized in this work are listed (Table 6.1). After 
restriction analysis the open reading frame of each vector was confirmed by 
sequencing. 
Figure 6.1: The destination vector pMGOrfA5’3’MARpuro5171. 
This vector is able to replicate in competent bacterial strains, to which it confers 
the ability to grow on agar containing Ampicillin. It contains sequences able to 
promote its recombination with "Entry-Clone" vectors, in addition to sequences 
essential for its insertion into the genome of a eukaryotic cell in highly transcribed 
regions. 
 
Figure 6.2: BamHI restriction analysis of the destination vector 
pMGOrfA5’3’MARpuro5171. 
 
 
M= 1Kb ladder (Fermentas) 
 
B= BamHI restriction analysis 
 
Expected fragment (bp) 
 
//BamHI= 7009 + 4891 + 1279 + 703 
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Table 6.1:  List of vectors used in the present work. 
pcDNA3.0hSOD1G93A pcDNA3  plasmid (Invitrogen)contains the 
human mutated G93A SOD1 cDNA 
sequence. Was used to obtain the 
hSOD1G93A cDNA sequence and for PAFs 
transfection experiments. 
pcDNA3.0hSOD1wt pcDNA3 plasmid (Invitrogen)contains the 
human wild type SOD1 cDNA sequence. Was 
used to obtain the hSOD1wt cDNA sequence. 
pENTRL1L2OligoSacISalI This plasmid is part of the Multisite Gateway 
system (Invitrogen) and was used in ligase 
reactions with both hSOD1G93A cDNA and 
hSOD1wt cDNA. 
pENTRL1L2-hSODG93A This vector was obtained from ligase reaction 
between the BamHI/XhoI fragment of 
hSOD1G93A cDNA and the 
pENTRL1L2OligoSacISalI plasmid 
pENTRL1L2-hSODwt This vector was obtained from ligase reaction 
between the BamHI/XhoI fragment of hSOD1wt 
cDNA and the pENTRL1L2OligoSacISalI plasmid 
pENTRL1L2-hSOD1G93A delSB  This plasmid was obtained trough double 
digestion of pENTRL1L2-hSODG93A with the 
restriction enzymes SalI and BamHI and was 
used in LR exchange reactions with the 
pMGOrfA5’3’MARpuro5171 vector. 
pENTRL1L2-hSOD1wtdelSB This plasmid was obtained trough double 
digestion of pENTRL1L2-hSODwt with the 
restriction enzymes SalI and BamHI and was 
used in LR exchange reactions with the 
pMGOrfA5’3’MARpuro5171 vector. 
pMGOrfA5’3’MARpuro5171 This destination vector is used in LR exchange 
reactions with both pENTRL1L2-hSOD1G93A 
delSB and pENTRL1L2-hSOD1wtdelSB vectors. 
pMG5’3’MARPuro5171-hSOD1G93A  This vector results from the LR exchange 
reactions between the 
pMGOrfA5’3’MARpuro5171 Destination Vector 
and the pENTRL1L2-hSOD1G93A delSB vector 
and is used in transfections experiments 
pMG5’3’MARPuro5171-hSOD1wt This vector results from the LR exchange 
reactions between the 
pMGOrfA5’3’MARpuro5171 Destination Vector 
and the pENTRL1L2-hSOD1wt delSB vector 
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Figure 6.3: The pcDNA3.0hSOD1G93A (a) and pcDNA3.0hSOD1wt (b) plasmids 
These plasmids contain the neomycin selection cassette under the SV40 promoter, while 
the transgene, consisting of the cDNA encoding or the mutated form of the human SOD1 
(a) or the wild-type one (b), is placed under the control of the CMV promoter. 
Figure 6.4: The restriction analysis of pcDNA3.0hSOD1G93A plasmid 
 
M= 1Kb ladder (Fermentas) 
Mu= MunI restriction analysis 
Stu= Stu I restriction analysis 
Expected fragment (bp) 
//MunI= 5940 
//Stu I = 4476 + 1464 
Figure 6.5: The “EntryClone” pENTRL1L2-hSODG93A(a) and pENTRL1L2-hSODwt (b) 
These vectors, in which was inserted the cDNA encoding or the mutated form of the 
human SOD1 (a) or the wild-type one (b), are able to replicate in competent 
bacterial strains, to which confer the ability to grow on agar containing Kanamycin. 
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Figure 6.6: Restriction analysis of pENTRL1L2-hSODG93A(a) and pENTRL1L2-
hSODwt (b) 
 
 
M= 1Kb ladder (Fermentas) 
 
S= SalI restriction analysis 
B= BamHI restriction analysis 
Pag= PagI restriction analysis 
Mu= MunI restriction analysis 
Hi = HincII restriction analysis 
Stu= Stu I restriction analysis 
 
 
Expected fragment (bp) 
 
// StuI = 3212 
// MunI = 3212 
// SalI =3212 
// BamHI =3212 
// PagI = 1620+952+640 
// HincII = 2997+215 
Figure 6.7: Restriction analyses of pENTRL1L2-hSOD1G93AdelSB vector. Same 
results are obtained from the restrictions of pENTRL1L2-hSOD1wtdelSB vector  
 
M= 1Kb ladder (Fermentas) 
S= SalI restriction analysis 
Pag= PagI restriction analysis 
Mu= MunI restriction analysis 
Hi = HincII restriction analysis 
Stu= Stu I restriction analysis 
Expected fragment (bp) 
// StuI = not digested  
// MunI = not digested 
// SalI = not digested  
// PagI = 1620+927+640 
// HincII = 2997+190 
b a 
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Figure 6.8: The pMG5’3’MARPuro5171-hSOD1G93A (a) and the 
pMG5’3’MARPuro5171-hSOD1wt (b) expression vectors 
These vectors are capable of promoting the transgene expression within 
eukaryotic cells through the action of the pCAGGS promoter. They are also able 
to confer to cells the ability to grow and replicate in medium containing 
puromycin, because of action of their puromycin-selection cassette under the 
control of SV40 promoter. 
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Figure 6.9: Restriction analysis of pMG5’3’MARPuro5171-hSOD1G93A 
expression vector. Same results are obtained from pMG5’3’MARPuro5171-
hSOD1wt vector restrictions.  
  
 
M= 1Kb ladder (Fermentas) 
Pag= PagI restriction analysis 
Eco= EcoRI restriction analysis 
Stu= Stu I restriction analysis  
 
Expected fragment (bp) 
// PagI = 7849+4527+506 
// EcoRI = 5238+3581+2292+1771 
// StuI = 7202+5680 
 
6.2 TRANSFECTION OF VECTORS INTO PIG ADULT 
FIBROBLASTS AND RELATED ANALYSIS 
6.2.1 pcDNA3.0hSOD1G93A 
The pcDNA3.0hSOD1G93A vector, carrying the mutated SOD gene, has 
previously been used by our group to transfect mouse astrocyte cell lines, 
obtaining a high transgene expression level. A pcDNA3.0hSOD1G93A mouse 
astrocyte lysate was used as a further positive control in WB analysis. To obtain 
comparison data, we decided to use the same construct for transfection of wild 
type PAFs. Thus we obtained 17 colonies of   pcDNA3.0hSOD1G93A PAFs that were 
analysed by both WB and ICC, revealing the SOD1G93A protein expression in 15 of 
17 PAFs colonies.  
Among the hSOD1G93APAFs colonies some presented a transgene expression 
pattern rather uniform while others showed a variegate expression pattern (in the 
same colony some cell showed a high expression and some were completely off!) 
(Figure 6.10). To explain this phenomenon, it is acceptable to assume a transgene 
position effect, due to its integration site in the host cell genome. 
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Figure 6.10: ICC conducted with rabbit polyclonal Ab 07-403 (Millipore) on 
pcDNA3.0hSOD1G93A PAFs colonies.  
[a] Human Umbilical Vein Endothelial Cells (Huvec) used as positive control. 
[b] wild-type PAF used as negative control. [c] PAF clone #C5 with uniform 
expression of human protein [d] PAF clone #B3 with variegate expression 
pattern. DAPI is the filter used to highlight the Hoechs nuclear staining. 
FITCH allows the detection of the fluorophore conjugated with the 
secondary anti-rabbit antibody and then the transgene expression. MERGE 
is the overlapping of the two images. 
 DAPI FITCH MERGE 
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6.2.2 pMG5'3'MARPuro-hSOD1G93A  
The transfection experiments conducted with the pMG5'3'MARPuro-
hSOD1G93A vector led to the isolation of 26 PAF clones, which were analysed by 
WB and ICC. All clones, as shown in Table 6.2, revealed transgene expression, to 
which a score was assigned. Four clones showed a transgene expression level 
lower than the control one (score 2), and three clones achieved the same score as 
the control. The remaining 19 clones showed a higher expression (Score ranging 
from 3 to 6) (Table 6.2 and Figure 5.1).  
Overall, the PAF colonies obtained by transfection of 
pMG5'3'MARPuro hSOD1G93A vector showed a transgene expression pattern 
higher and more uniform than those shown by the colonies obtained by 
transfection of the vector pcDNA3.0hSOD1G93A: this phenomenon, is attributed to 
the greater effectiveness of the pCAGGS promoter to induce the expression of the 
human transgenic protein in the swine genome. 
Table 6.2:  List of PAF clones transfected with pMG5’3’MARPuro5171-hSOD1-
G93A vector. 
Clone Score  
1A1 3 
1A2 6 
1A4 1 
1A5 5 
1B1 3 
1B3 4 
1B6 6 
1C1 1 
1C2 2 
1C6 4 
1D1 5 
1D2 1 
1D5 4 
1D6 5 
1E1 6 
1E2 4 
2A1 6 
2A2 6 
2A3 5 
2A4 1 
2A5 4 
2A6 4 
2B2 4 
2C1 5 
2C2 5 
2C3 4 
In this table clones obtained by 
pMG5’3’MARPuro5171-hSOD1-G93A 
vector transfection in wild-type PAF are 
reported. A score indicating the 
transgenic protein expression level, 
compared to the positive control one 
(score=2), was assigned to each clone. 
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6.3 Somatic Cell Nuclear Transfer (SCNT) 
The hSOD1G93A PAF colonies to be used for NT experiments were 
chosen depending on protein expression level shown. In particular, the 1A1, 1A2, 
1B1, 1C2, 1D1, 1D2, 1E2, 2A2, 2A6, 2B2, 2C1 and 2C3 pMG5’3’MARPuro-
hSOD1G93A PAFs colonies and the # C5 pcDNA3.0hSOD1G93A Paf colonies were 
selected. Eight cloning experiments were conducted. In the first and second SCNT 
experiment the colony #C5 has been employed, as nuclei donor. In the third and 
fourth experiment, a pool of clones (1A1, 1C2, 1D2 and 1E2) was used as a nucleus 
donor. In the fifth and sixth experiment a pool composed of 1B1, 1D1, 2C1 and 2B2 
clones was employed, while a pool composed of 1A2, 2A2, 2A6 and 2C clones was 
employed in the seventh and eighth experiment. All the SCNT experiments 
conducted are listed in Table 6.3 where viable embryo percentages (ranging from 
31,58% to 50,50%) can be appreciated. These results are in line with those obtained 
from similar experiments conducted with other transgenes (data not shown). 
Table 6.3: List of cloning experiments and in vitro embryo development 
data  
The “ID clones” column shows the names of hSOD1-G93A PAF clones that 
composed the cells pool, used as nuclei donors. In “N° SCNT” column the number 
of SCNT experiments is reported. The “average score” column indicates the 
transgene expression level owned by the pool of PAF clones. “N” is the number of 
pairs cytoplasts/PAF formed after the fusion. “Cl” is the number of segmented 
embryos and its value is compared to the total percentage of reconstructed 
embryos. “Mc/Bl” indicates the number of compact morulae and blastocysts at 
the sixth day of in vitro culture. “Tot embryo” indicates the number of viable 
embryos, with the relative percentage value obtained by comparison with the 
initial number of manipulated oocytes. “Piglets” indicates the pregnancy 
outcome, with the number of vital and stillborn piglets obtained. 
Piglets ID clones 
N° 
SCNT 
average 
score 
N Cl % 
Mc/Bl 
D6 
TOT 
embryo 
% 
Vital/stillborn 
#C5 1 1 209 189 90,43% 10 mc,56 bl 66 31,58% No pregnancy 
#C5 2 1 206 195 94,66% 78 bl 78 37,86% No pregnancy 
A1,E2,C2,D2 3 2 195 181 94,66% 8 mc, 61 bl 69 35,38% No pregnancy 
A1,E2,C2,D2 4 2 204 185 92,82% 11mc, 63 bl 74 36,27% No pregnancy 
B1, 2B2, 2C1,D1 5 3 200 172 86,00% 21 mc, 54 bl 75 37,50% 6/4 
B1, 2B2, 2C1,D1 6 3 209 151 72,25% 31 mc, 47 bl 78 37,32% 5/2 
1A2,2A6,2A2, 2C3 7 5 205 179 87,32% 96 bl 96 46,83% 3/1 
1A2,2A6,2A2, 2C3 8 5 202 178 88,12% 102 bl 102 50,50% 2/7 
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6.4 Development to term of SCNT embryos 
derived from hSOD1G93A PAFs  
The transfer of 638 embryos to eight recipients sows resulted in four 
pregnancies. The 4 pregnant sows received 75, 78, 96, 102 embryos obtained from 
the fifth, sixth, seventh and eighth SCNT experiment respectively (Table 6.3). 
Pregnancies were developed to term and resulted in the birth of 10, 7, 4 and 9 
piglets with a mean efficiency of blastocyst development to term of 8,78%. Among 
produced piglets 16 were vital and 12 were stillborn. Five piglets survived 
artificial hand raising and weaning and developed normally. The remaining 11 
piglets died within 48–96 h from birth due to events commonly reported in 
commercial herds (i.e. some piglets were not nursing,  others developed diarrhoea, 
pneumonia etc). In Table 6.4 the ID that was assigned to the transgenic piglets are 
summarized.   
Table 6.4: hSOD1G93A piglets ID. 
N° SCNT Piglet ID Healt Status 
5 052-1 stillborn 
5 052-2 stillborn 
5 052-3 stillborn 
5 052-4 stillborn 
5 165 Dead at 3 days  
5 166 Dead at 15 days 
5 167 Dead at 15 days 
5 168 Alive  
5 169 Dead at 6 days 
5 171 Dead at 5 days 
6 053-1 stillborn 
6 172 Dead at 4 days 
6 173 Alive  
6 174 Alive 
6 175 Dead at 5 days  
6 176 Dead at 6 days  
7 201 Dead at 3 days  
7 202 Dead at 9 days  
7 203 Dead at 1 days  
7 137-1 stillborn 
8 204 Alive 
8 205 Alive 
8 143-1 stillborn 
8 143-2 stillborn 
8 143-3 stillborn 
8 143-4 stillborn 
8 143-5 stillborn 
8 143-6 stillborn 
8 143-7 stillborn 
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6.5 Transgene Integration Analysis  
Trough PCR analysis it has been possible to detect the transgene 
presence in the swine genome. In Figure 6.11 it is possible to appreciate the 290pb 
lane corresponding to transgene amplification in piglet 168 genomic DNA (α). 
Lanes β-λ show the pENTRL1L2-hSOD1G93AdelSB DNA plasmid amplification in 
serial dilution, while μ show no amplification signal in swine wild type genomic 
DNA.  
With the aim to establish the integration pattern of the construct 
containing the ALS-related human SOD1G93A mutated protein in the swine 
genome, Southern blot analysis was performed on DNA extracted from all piglets 
obtained during the project. In particular, Figure 6.12 shows the results obtained 
on DNA from piglets born after the fifth and sixth embryo transfer experiments in 
which B1, 2B2, 2C1 and D1 PAFs-SOD1G93A colonies was employed as nuclei 
donors. The analysis revealed four different integrations patterns (identifiable 
with blue ♠,♣,♦,♥ symbols), corresponding to the four different PAFs-SOD1G93A 
colonies. Figure 6.13 shows the results obtained on DNA from piglets born after 
the seventh and eighth embryo transfer experiments in which nuclei come from 
1A2, 2A6, 2A2, and 2C3 PAFs-SOD1G93A colonies. Similarly to that observed in 
figure 6.13, it is possible to appreciate four different transgene integration 
patterns, that are indicated with red ♠,♣,♦,♥ symbols and correspond to 1A2, 
2A6, 2A2, and 2C3 PAFs-SOD1G93A colonies. 
Figure 6.14 shows an overview of data obtained from SB analysis: the alive pigs 
ID, who have reached one years of age, are highlighted with green color. Among 
the five live pigs are represented four transgene integration patterns. The 
increasing integrations numbers is also reported. 
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Figure 6.11: PCR analysis. 
The picture show the results obtained from PCR analysis of various templates.   M= 
molecular weigh; α= 168 piglet genomic DNA at [1ng/µl] of concentration; β, γ, δ, 
ε, ζ, η, θ, ι, κ, λ= pENTRL1L2-hSOD1G93AdelSB plasmid at serial dilution ranging from 
[1ng/µl] to [1ag/µl] µ=Wild type swine genomic DNA. W= water. 
 
 
 
Figure 6.12: Southern blotting of DNA from transgenic piglets born after 
fourth e fifth cloning experiments. 
M = λ//HindIII ; 165,166,167,168,169,171,052-1, 052-2, 052-3, 052-4, 172, 173, 174, 
175, 176 = piglets ID. WT = wild type pig. The blue ♠,♣,♦,♥ symbols correspond to 
the four different transgene integration patterns obtained in transgenic piglets 
born after fifth and sixth cloning experiments 
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Figure 6.13: Southern blotting of DNA from transgenic piglets born after 
seventh and eighth cloning experiments. 
M = λ//HindIII ; 201, 203, 202, 143-1, 143-5, 143-4, 137-1, 204, 204, 205, 143-6, 143-7 
= piglets ID. WT = wild type pig. The red ♠,♣,♦,♥ symbols correspond to the four 
different transgene integration patterns obtained in transgenic piglets born after 
seventh and eighth cloning experiments.  
 
Figure 6.14: Transgene integration pattern summarizing chart.  
Alive piglets ID is indicate with green. The growing order of transgene integrations 
number relative to piglets that have reached adulthood is reported. 
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6.6 Detection of hSOD1G93A expression in 
stillborn piglets and living animals 
Fibroblasts obtained from ear biopsy of both vital and stillborn 
piglets, were analyzed by ICC and revealed a transgene expression level 
comparable with that of PAF used as nuclei donors (Figure 6.15). 
Furthermore, IHC and WB analysis were performed on dead and 
stillborn piglets tissues. Immunohistochemistry (Figure 6.16) was performed on 
coronary sections of all FFPE samples. Analysis performed by GTX 100659 
revealed granular mutant protein aggregates in neurites and perikarya in brain 
(from area hypothalamica lateralis to the third ventricle), spinal cord (especially at 
the thoracic level), peripheral nerves (brachial plexus and sciatic nerve) and in the 
Enteric Nervous System. The same brain areas also revealed ubiquitine 
immunoreactivity characterized by intracytoplasmatic aggregates, while we 
couldn’t detect any ubiquitin staining in spinal cord and in peripheral nerves.  
Double immunofluorescence analysis revealed NeuN reactivity in 
cells displaying SOD1 aggregates, confirming mutated protein accumulation in 
neurons (Figure 6.17). Anyway, considering the extremely young age of our 
piglets and the brain areas involved, the pathogenic role of these protein 
aggregates in the hSOD1G93A swine requires further investigations.  
Snapshot spinal cord samples were homogenized and analysed by 
WB. The transgenic protein was revealed using both antibodies (07-403 Millipore 
and GTX 100659 Genetex). In Figure 6.18 it is possible to see two bands, 
corresponding to the two SOD1 isoforms: the endogenous swine protein 
displaying a lower molecular weight (16 KDa) and the human transgenic one, with 
a higher molecular weight (18 KDa). 
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Figure 6.15: ICC on PAF biopsied from the 5 transgenic living pigs.  
Picture shows FITCH signal obtained with Millipore 07-403 antibody staining. hSOD1-
G93A expression is revealed in all animals analyzed. [A] and [B] display staining in 
wild-type PAF and Huvec cells, respectively used as negative and positive 
controls. [C] Pig 168 is characterized by a moderate cytoplasmic and perinuclear 
staining. [D] Pig 173 displays an intense cytoplasmic labelling along with a 
perinuclear ring, noticeable in some cells. [E] and [F] show nuclear labelling with 
faint cytoplasmic staining detected in pigs 204 and 205 respectively. [G] Pig 174 
displays a faint cytoplasmic staining. Perinuclear rings and faint nuclei labelling 
can also be observed in some cells. [H] shows intense cytoplasmic labelling 
detected in cells from stillborn piglets 169. 
 
Figure 6.16: Genetex GTX 100659 IHC on FFPE piglet samples.  
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In panel A it is possible to appreciate hSOD1-G93A staining in the ileum with 
clusters of positive cells next to the muscolaris mucosa. Panels B and C 
show deposition pattern at the level of area Hypothalamica lateralis. In the 
same area (panel D), it is also possible to appreciate isolated cells 
displaying hSOD1-G93A staining. Panel E shows a bundle of positive cells 
lining the optic tract. Panel F displays deposition pattern in the spinal cord: 
it is possible to appreciate granular aggregates along fibres. 
 
 
 
 
Figure 6.17: Double IF on hSOD1G93A swine spinal cord. 
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Double immunofluorescence analysis reveals NeuN reactivity (red) in cells 
displaying SOD1 aggregates (green), pointing out mutated protein 
accumulation in neurons. 
 
Figure 6.18: WB on stillborn piglets spinal cord. 
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The figure displays results obtained with Millipore 07-403 at the dilution 1:1000. In all 
hSOD1G93A piglet tissues (spinal cord, brain, muscle) it is possible to appreciate two 
lanes, corresponding to the two SOD1 isoforms: the endogenous swine protein 
displaying a lower molecular weight (16 KDa) and the human transgenic one, with 
a higher molecular weight (18 KDa). On the contrary on tissues homogenate from 
non-transgenic pigs, used as negative control, only the band with lower molecular 
weight is present (16 KDa). Mw: molecular weight; Wt: wild type; Tg: transgenic; 
SC: spinal cord; CNS: Central Nervous System; Mus: muscle. 
 
6.7 Phenotypic characterization and hSOD1G93A 
swine line establishment 
At the time of writing, the five transgenic swine have reached the age 
of one year and four of them are healthy, since one of them recently died from a 
bacterial infection.  
Clinical and Neurological picture assessment 
As far as characterization of the hSOD1G93A swine is concerned, a complete 
examination is ongoing by simultaneous evaluation of general clinical and 
neurological aspects, by biochemical and proteomic investigations and, by 
electrophysiological and neuroimaging analysis. Animal’s phenotype will be 
analyzed as thoroughly as possible by means of repetitive evaluations along the 
whole time course of the disease/project. Actually, a careful clinical monitoring on 
the four living swine, conducted using the protocols described above is ongoing, 
in order to recognize the ALS symptomatic onset. Periodical blood samples are 
taken from hSOD1G93A pigs and controls and analyzed with a standard 
biochemical profile, with no variation between controls and transgenic pigs has 
yet been detected.  
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Locomotor function assessment, electrophysiological and neuroimaging 
analysis. 
Since in G93A mice an early ALS clinical manifestation is the development of 
locomotor deficits, our aim is to promptly detect gait alterations in the hSOD1G93A 
swine. A specifically-designed 3D Motion Capture System has been developed, in 
collaboration with Prof. A. Rainoldi (SUISM, Turin University Physical Education 
Research Center), to evaluate objectively the locomotion capability of animals and 
to detect minimal and precocious gait alterations (Figure 6.19).  
So far, no gait alteration has been detected. This procedure will be continued for 
the entire duration of the experiment and, in case of encouraging results of the 3D 
motion capture Pilot-study, this analysis will be implemented. 
Figure 6.19: 3D motion Capture. 
The figure shows a 3D Motion Capture technique: the animals are subjected to 
trichotomy and  marked with withe atoxic coluourant in the main joints area. 
Subsequently pigs are filmed during gait: the green background is needed for the 
next computer movie processing. Through a software it is possible to create a 
objective gait profile of each pig and thus possibly highlighting gait impairments.  
 
With regard to the electrophysiological analysis, in collaboration with Prof. R. 
Merletti (Laboratory for Engineering of the Neuromuscular System, Politecnico, 
Turin), an EMG protocol is in progress of development. With regard to the MRI 
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analysis, we are looking to obtain the necessary permissions to use the scanner 
located at Neuroradiology Department of CTO Hospital, Turin. 
Proteomic investigations  
Plasma samples have been collected at one year of age, and then every four 
months, in order to assess whether proteome profile changes are detectable in the 
hSOD1G93A swine. A global proteomic approach to characterize as much as 
possible the entire protein repertoire in animal plasma is ongoing and includes a 
mono-dimensional electrophoresis (1DE) approach for protein pre-fractionation 
and high-accuracy mass spectrometry (MS) for protein identification.  
This strategy, called label-free quantitative proteomics, provides the most 
abundant protein identifications because it overcomes the limited dynamic range 
of protein separation inherent to bi-dimensional electrophoresis-based proteome 
analysis. Moreover it is capable of accurately identifying and quantifying 
thousands of peptides simultaneously, allowing a comprehensive protein profile 
with relative quantitative information for all the proteins identified in a sample 
using the mass spectral output. In this study we used spectral counting, which 
provides an estimation of the relative amounts of each identified protein in the 
different samples. Because of the low number of transgenic animals, this 
proteomic approach is a pilot investigation to assess whether proteome profile 
changes in plasma are detectable in a transgenic swine model for ALS when 
compared to the healthy counterpart. To date no differently expressed proteins 
between hSOD1G93A swine and controls have been yet identified. 
Post-mortem analysis 
On tissue samples from the one year-old died hSOD1G93A pig a complete banking 
has been performed. Homogenates coming from various tissues have been 
analyzed by WB. Interestingly, it was found that the one year-old pig muscle 
shows an increased accumulation of hSOD1G93A, when compared to that of 
stillborn piglets, and that this is reminiscent of what occurs in transgenic mice, as 
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shown in (Figure 6.20). Confirming this phenomenon, also the IHC analysis shows 
a hSOD1G93A deposition pattern overall slightly more pronounced. 
 
Figure 6.20: WB on tissues from stillborn piglets and on one year old pig. 
The figure displays the results obtained with Millipore 07-403 at the dilution 1:1000 
on tissues from the spinal cord of G93A mouse, wild type swine, stillborn piglets and 
from one year old pig. Mw: molecular weight; Wt: wild type; Tg: transgenic; SC: 
spinal cord; CNS: Central Nervous System; Mus: muscle. 
 
 
hSOD1G93A swine line establishment 
As far as semen collection and banking is concerned, three founder boars have 
been generated and characterized for different transgene integration sites. Two 
boars are one year old and one is 10 months old. They are trained for artificial 
collection of semen over a dummy. Since they are cloned transgenic minipigs, 
training is more difficult than in commercial breeds and animals don’t adapt to 
this procedure: to overcome this problem seminal material has been collected by 
electro-ejaculation. The collected semen has been both used in artificial 
insemination and frozen to be used later and to maintain a “back-up” of the 
genetic line. Two wild type sows have been artificially inseminated by 
laparoscopy and one of them is currently pregnant. This encouraging result gives 
hope that the ALS swine model can be maintained by sexual reproduction.  
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In the decades since the first generation of transgenic mice produced 
by pronuclear injection [Gordon et al., 1980], transgenic animals have become 
indispensable tools for studying gene function, development, and regulation. 
Transgenic animals have already provided key insights into the brain and 
behavioral processes of relevance for human brain disorders. 
The production of genetically modified live domestic animals 
remains a demanding task, especially for pigs (for review, Lavitrano et al., 2006; 
Nagashima et al., 1995; Niemann et al., 2005). Pronuclear injection and retroviral 
infection approaches were much less efficient in pigs than in mouse [Hammer et al., 
1985; Pursel et al., 1989; Wheeler & Walters, 2001]. Although lentiviral transgene 
delivery offers an efficient method for the generation of transgenic pigs [Whitelaw 
et al., 2004], the use of lentivirus (HIV-1; EIAV) poses many safety and ethical 
concerns, due to the their proven ability of activating oncogenes as well as to the 
possibility of re-acquiring their pathogenic characteristics.  
The recent introduction of SCNT [Campbell et al., 1996; Wilmut et al., 
1997] has opened a new way for gene targeting in domestic animals, which may 
prove useful for the pig. Here, genetic manipulation is performed in somatic cell 
cultures, and the modified cells are later used as donors for nuclear transfer. In 
spite of the inefficiency of nuclear transfer, the first live offspring produced by 
porcine SCNT were obtained only 4 years after the birth of Dolly, simultaneously 
in three independent groups [Betthauser et al., 2000; Onishi et al., 2000; Polejaeva et 
al., 2000]. During the past 5 years, birth of somatic cell cloned piglets has been 
reported in laboratories of eight countries: UK, USA, Japan, Australia, Germany, 
Italy, Korea and China. 
The overall efficiency remains low; only 1–2% of the transferred embryos develop 
to term, and the establishment of pig cloning as a routine procedure is a 
formidable task. Nonetheless, cloning of pigs has been more successful than rat 
cloning, which has only been accomplished once, by SCNT [Zhou et al., 2003]. 
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Cloning of monkeys has likewise been reported only once [Chan et al., 2001], a 
procedure which has raised particular ethical considerations [Gagneux et al., 2005]. 
The use of pigs in experimental brain research was advocated more 
than 30 years ago. However, factors favouring the continuing and nearly exclusive 
use of rodents include the ease of housing and handling of small laboratory 
rodents. In contrast, the use of non-human primates was favoured due to the 
inherently greater similarity to human brain function. Nonetheless, the use of pigs 
within neuroscience has increased in the past decade to an extent, which far 
exceeds that of other farm large animals, such as, for instance sheep. However, 
basic knowledge about the anatomy, physiology and development of the pig brain 
is still scanty. At the same time, the continued extensive use of non-human 
primates in neuroscience research has become problematic due to their particular 
requirements for housing and handling, the lack of uniform quality with respect to 
microbiological status and group comparability and, importantly, ethical 
considerations. In a ‘relational perspective’ where emotional bonds between 
humans and animals are recognized, the use of pigs in neuroscience will probably 
become more ethically acceptable than is the use of primates, but may remain less 
acceptable than the use of rodents. 
As reviewed above, pigs fulfil many of the requirements for a good 
experimental animal species for studying brain and behavioral processes and 
could eventually replace the use of monkeys for many neuroanatomy and 
neurochemistry studies. Wider use of pigs in research could facilitate 
extrapolation of preclinical findings to humans, especially in important research 
areas wherein obvious dissimilarities in brain structure and function render 
rodents less comparable to humans. Many of the prerequisites for conducting 
neuroscience research are fulfilled for pigs, including the need for standardized 
and inbred laboratory breeds, and an advanced knowledge of the general anatomy 
and physiology, housing, handling and experimental procedures.  
Discussion and Conclusions 
134 
The recent advent of imaging technology for studying brain function and structure 
in vivo has benefited from the relatively large size of the pig brain. Availability of 
a high quality normalized cDNA library for porcine brain has recently made 
possible microarray technologies and functional genomics for studies of brain 
function in pigs [Nobis et al., 2003]. To date, several specific pig models of brain 
disorders have been suggested or established.  
Current developments in organ transplantation indicate that the pig may be 
suitable as brain tissue donor for humans afflicted by neurodegenerative diseases 
[Deacon et al., 1997]. The model of acquired Parkinsonism in Göttingen minipigs 
[Mikkelsen et al., 1999], and a model of diffuse brain injury in pigs with relevance 
for Alzheimer’s disease have been described [Smith et al., 1999].  
Rapid progress in basic biomedical research, mostly conducted on 
small laboratory rodents, has generated a huge amount of experimental data. 
However, before this newly gained knowledge can find its way into designs of 
new therapies, we need to validate it on animal models more closely related to 
humans. On the basis of selection of examples adduced in this thesis, we are 
convinced that the laboratory miniature pig can represent such a model. In spite of 
the disadvantages presented by housing requirements and large body size, the 
advantages of using pigs as an experimental animal for modelling human brain 
disorders has become increasingly evident. Compared to non-human primates, 
the primary candidate species for bridging this gap, pigs are cheaper and easier to 
maintain in controlled conditions. A considerable amount has been learned about 
pig brain anatomy and neurochemistry. The swine brain is gyrencephalic and 
more similar in anatomy, growth and development to the human one rather than 
those of common small laboratory animals. Moreover its large size allows detailed 
identification of cortical and subcortical structures by imaging techniques. 
Furthermore, swine offers numerous opportunities regarding transgenic 
manipulations of neural genes.  
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Their human-like physiology assures a high relevance of the data obtained in this 
species for human-related therapeutic research. With the miniature pig gestation 
period of 114 days and litters up to 12 piglets, enough experimental animals can be 
obtained, and a lifespan of 12–18 years allows long-term experiments evaluating 
the safety and efficacy of possible therapies.  
As described in this text, miniature pigs are already extensively used in several 
fields of biomedical research, and we firmly believe that the importance of these 
animals as a biomedical model will increase even further in the near future. Thus, 
the development of animal models of human brain disorders in pigs can benefit 
from the full range of neuroscience techniques, as an alternative to research 
exclusively in rodents and non-human primates. 
 
The present thesis reports the creation of a novel animal model, 
consisting in a transgenic swine carrying the human SOD1 gene with the G93A 
mutation responsible for the onset of ALS. This model is useful in studying such a 
disease and to develop novel diagnostic markers and therapeutic approaches for 
the human species. To achieve this goal, we were able to obtain a stable expression 
of exogenous gene (hSOD1G93A) in a consistent, reproducible way and in the long 
term in living animals. Our experimental approach turned out to be successful and 
we managed to produce a large number of piglets (mean efficiency of blastocyst 
development to term of 8,78%), five of which reached the adulthood. All pigs 
generated express hSOD1G93A, thus allowing us to exclude a hSOD1G93A expression- 
related toxic effect and simultaneously to confirm the effectiveness of our SCNT 
knowhow with obtaining a percentage of born animals far higher than that 
reported in the literature. Since hSOD1G93A expression was revealed in tissues from 
dead and stillborn piglets, our vector proved to be a suitable cassette for the 
expression of multiple genes relevant to human inherited diseases as far as tissue 
specificity is not required.  
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We decided to use in SCNT experiments a pool of donor cells showing different 
transgene expression level in order to minimize the risk of using cell clones unable 
to generate a viable animal. As a matter of fact, since this is the first hSOD1G93A 
swine model produced so far, no data are available about the toxicity related to 
transgene expression level in the early stage of porcine embryonic development 
and after embryo transfer in sows. Since donors cells with different expression 
levels have been employed in SCNT, the cloned piglets present variable transgene 
expression levels depending on the particular cell from which they have been 
created. Among the 4 boars available, 3 different transgene integration sites have 
been identified. Semen collected from these animals has been used in breeding 
experiments to fertilize two wild type sows, and one of them is currenly pregnant. 
After farrowing the F1 progeny, of which, accordingly to Mendelian laws, 50% 
will inherit the disease, will be assessed for transgene expression levels and, by 
further inbreeding, the ALS swine line will be brought to homozygosity. Expected 
generation interval is about 12-15 months. 
 
The SOD1 protein is an enzyme with antioxidant function acting by 
reducing the superoxide ion (O2-) level, a toxic free radical product during the 
oxidative cellular metabolism. The superoxide ion is capable of altering proteins, 
membranes and DNA. The involvement of a mutated protein in its pathogenesis 
leads to include ALS in the proteinophaty family. Studies on transgenic rodent 
models were aimed at understanding the mechanisms by which mutated SOD1 
gene leads to the onset of ALS: they have ruled out that the motor neuron 
degeneration is the result of loss of dismutase activity and allowed to detect the 
formation of aggregates of ubiquitinated proteins in affected tissues, among other 
containing the mutant SOD1: it is assumed that these inclusions protein play a role 
in the interruption of cell functions damaging mitochondria, proteasomes, 
mechanisms of protein folding or other proteins.  
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Unlike rodent models that show an extremely high transgene expression level and 
a rapid disease course [Bendotti & Carrì, 2004], our swine model presents an 
expression level comparable to that of human patients, where a single allele 
mutation results in the aforementioned toxic gain of function.  
Piglets expressing the hSOD1-G93A protein, which already express the mutated 
protein at birth, are expected to show the full degeneration of upper and lower 
motor neurons, leading to muscle weakness, atrophy and evolving to complete 
paralysis, with times and modalities similar to those that occur in ALS patients.  
On one hand this could result in a longer pre-clinical phase and in an increase in 
animal maintenance costs, on the other hand the present hSOD1G93A swine 
represents an invaluable opportunity to find early biomarkers and a closer and 
more faithful model to reproduce human pathology since ALS is typically an 
adult-onset disease. 
 
Currently, an animal model recapitulating all the ALS crucial aspects 
has not yet been produced. However, since increasing difficulties are emerging in 
translating information gained from rodent models into therapeutic options for 
ALS patients, there is an urgent need for an intermediate research system. We 
believe that a swine model provides this essential bridge between insights gained 
from rodent models and the reality of treating a human disease. 
As a matter of fact, most preclinical studies on ALS are carried out in rodents, such 
as mice and rats overexpressing mutant SOD1. They have provided important 
information regarding the pathogenesis of the disease, nevertheless, one of the 
limit of these models is that they exhibit a loss of spinal but not of cortical motor 
neurons and the cortical spinal tract is poorly represented in these animals. In this 
respect, the anatomy of the pig motor cortex shows more similarities with that of 
humans, allowing investigating whether the loss of primary motor neurons is a 
cause or a consequence of the loss of spinal motor neurons.  
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Another advantage of the pig as a model of ALS is the possibility to work on a 
large amount of nervous system material which allows a series of analyses from 
the same animal. At present ALS pathogenetic mechanisms are poorly 
understood. In primis the availability of a swine model capable of reproducing the 
disease could allow to disclose still unknown ALS traits. 
Particularly we will be able to study the clinical presentation of the disease, 
evaluating similarities and/or differences with the human condition. By a detailed 
examination of the clinical symptoms of the experimental swine hypotheses on the 
pathogenesis of the disease will be put forward. Consequently, we will try to 
delineate and characterize the involved pathogenetic mechanisms by investigating 
the supposed molecular pathways at their basis.  
Since this is the first swine ALS model produced so far, the amount 
of data, obtained from animals characterization, will be enormous and hopefully, 
unexpected results or ground-breaking ideas could rise. We are expecting to reach 
an exhaustive characterization of this new animal model. Specific clinical aspects, 
such as neurological clinical picture, neuromuscular function and blood 
biochemical parameters, will be defined as thoroughly as possible by means of 
repeated evaluations along the whole time course of the disease/project. 
All pigs will be neurologically examined according to an optimized protocol. Each 
animal will be examined by the same veterinarian. A standardized data collection 
form will be filled. Neurological examination will follow a standard procedure to 
assess mental status, posture, gait, postural reactions and proprioception, cranial 
nerves, spinal reflexes and sensitivity. In each pig the hind limbs' proprioceptive 
positioning reaction (knuckling over), the wheel barrowing reaction (with and 
without the neck extended) will be tested to evaluate postural reactions and 
proprioception. Spinal reflexes will be assessed by the standard test for flexor 
reflex, wherein the reflex is stimulated by pinching the foot with a forceps in the 
standing pig. If the response will be diminished or absent, the pig will be 
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examined in the lateral recumbent position, checking on each side the flexor, 
patellar and cranial tibial reflexes on the hind limbs and the flexor and extensor 
carpi radialis reflexes on the front limbs. 
ALS patients show different onset, regarding both body side and age, and may 
present different courses of disease. The clinical management is based on 
neurological examination and functional rating scales. In daily clinical practice of 
neurologists trained in ALS this scales demonstrated to be reliable and useful. 
We will attempt to correlate these clinical scales to ALS swine models and create a 
clinical reliable instrument within the global characterization, finding analogies 
with the disease in man and pig. Specifically, the ability to swallow will be 
assessed using direct and indirect tests and respiratory failure will be evaluated 
clinically, by performing blood gas analysis. 
Periodical analyses on blood, urine and CSF from experimental pigs will hopefully 
confirm the already known role of some molecules in the pathogenesis of the 
disease and lead to the discovery of other probable biochemical markers 
characterizing ALS neurodegenerative process. Finding a model more similar to 
man will be fundamental for clinical and preclinical trials in ALS. 
The identification of previously unraveled diagnostic markers of ALS will enable 
to recognize new therapeutic targets for the disease. This would further allow 
starting in the future clinical trials for anti-ALS drugs in the swine model, in the 
hope that possible positive outcomes obtained in this species may be efficaciously 
transferred to man. 
We must actually remember that the majority of the preclinical trials for ALS 
performed until recently have been carried out in the mouse model and, even if 
successful in this species, they further failed to prove their efficacy in human 
beings. We are instead confident that the findings from the drug tests in the swine 
model, which is closer to man's physiology than the mouse, could really be 
transferable to ALS affected patients. 
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On 4th May 2012 our research group filed a patent application with title: “Novel 
transgenic animal model of Amyotrophic Lateral Sclerosis” that is become 
advantageously available for ALS researchers (Figure 7.1). 
Figure 7.1: The patent application: “Novel transgenic animal model of 
Amyotrophic Lateral Sclerosis”. 
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